English translation

Summary of Financial Statements for the Fiscal Year Ended December 31, 2012
[Japanese GAAP] (Non-consolidated)
Company Name
Securities code

SymBio Pharmaceuticals Limited
4582
Representative Director, President and Chief
Executive Officer
Director, Chief Financial Officer

Representative

Contact person
Ordinary Annual General
March 28, 2013
Meeting of Shareholders
Scheduled date to file Securities
March 29, 2013
ReportSupplementary materials for the
Yes Nofinancial statements
Holding of earnings performanceYes
review:

February 14, 2013
Listing: Osaka Securities Exchange
URL http://www.symbiopharma.com/
Fuminori Yoshida
Hiroki Maekawa
Date of dividend
payment (plan)

TEL 03(5472) 1125―

No (For securities analysts and institutional investors)

Millions of yen – rounded down, unless otherwise stated
1. Business Results for FY 2012 (January 1, 2012 to December 31, 2012)(1) Operating results

FY 2012FY 2011Net sales
Millions of yen
1,955
1,882

(Percentages indicate year-on-year changes.)
Ordinary income (loss)
Net income (loss)
Operating income (loss)% Millions of yen% Millions of yen% Millions of yen%
3.9(1,700)(1,729)(1,733)29.8(2,066)(2,095)(2,104)-

Net income (loss) per share

Diluted net income per
share

Yen

(90.60)(143.60)

FY 2012FY 2011(Reference) Equity in earnings

FY 2012

Yen-

Ratio of net
Ratio of ordinary Ratio of operating
income (loss) to income (loss) to income (loss) toequity (ROE) total assets (ROA)
net sales%%%- Millions of yen(30.2)(39.4)(27.1)(36.4)FY 2011(87.0)(109.8)- Millions of yen(2) Financial position

FY 2012FY 2011

Total assets
Millions of yen

Net assets
Millions of yen

5,502
7,256

4,899
6,605

(Reference) Net assets excluding subscription rights to shares:
FY 20124,872 Millions of yen

Equity ratio%

Net assets per share
Yen

88.6
91.0

254.71345.28FY 20116,605 Millions of yen(3) Cash flows
Cash flows from operating Cash flows from investing Cash flows from financing Cash and cash equivalents
activities
activities
activities
at the end of the year
Millions of yen
Millions of yen
Millions of yen
Millions of yen
FY 2012FY 2011(1,658)(2,074)

(410)
(117)

(0)
4,610

4,240
6,310

2. Dividends
Annual dividend per share
1st quarternd

2 quarterYen-

FY 2011
FY 2012FY 2013 (Forecast)

3rd quarter

Yen
0.00
0.00
0.00

Fiscal Year End

Yen-

Total dividends

Payout ratio

Millions of yen
0
0

%
0.0
-

Full year

Yen
0.00
0.00
0.00

Yen
0.00
0.00
0.00

Ratio ofdividends to
net assets
%
0.0
0.0

3. Earnings forecasts for FY 2013 (January 1, 2013 to December 31, 2013)

Net sales
Millionsof yen

%

1,927

(1.4)

Full Year

Operatingincome (loss)
Millions%of yen(Percentages indicate year-on-year changes.)
Ordinary
Net income (loss)
Net income (loss)
income (loss)
per share
Millions
Millions%%Yenof yenof yen(1,889)(1,922)--(1,926)-(81.03)

Notes:(1) Changes in Accounting Policies, changes in accounting estimates and restatements after error corrections(a) Changes in accounting polices due to revision of
accounting standards:(b) Changes in accounting polices due to otherreason:Yes ・ NoYes ・No(c) Changes in accounting estimates:

Yes ・ No(d) Restatements after error corrections:

Yes ・ No

(2) Number of shares outstanding (Common stock)(i) Number of shares outstanding at the end of
the year (including treasury stock)(ii) Number of shares of treasury stock at theend of the year(iii) Average number of shares during the year

FY 2012

19,130,900shares

FY 2011

19,130,900shares

FY 201275shares

FY 201175 shares

FY 2012

19,130,825shares

FY 2011

14,655,716shares(Note) Refer to “Per share information” on Page 49 for number of shares that forms the basis for calculating net income (loss) per
share.
* The status of the annual audit
The audit of financial statements as required by the Financial Instruments and Exchange Act is proceeding as of the date of thisdisclosure document.
*Explanation regarding the appropriate uses of earnings forecasts and other matters(Notes on the forward-looking statements)
All forecasts presented in this document including earnings forecasts are based on the information currently available to the
management and the assumptions that we judge reasonable. Actual results may differ substantially from these forecasts due tovarious factors. Regarding the assumptions on which the earnings forecasts are based and its usage, please refer to “Businessresults analysis” on Page 1 of the attachment.

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

Index of the attachment
1. Business results……………………………………………………………………………………………………….………. 1(1) Business results analysis ……………………………………………………………………………………………...….. 1(2) Financial position analysis ………………………………………………………………………………………………. 3(3) Basic policies concerning profit distribution and dividends …………………………………………………………..… 4(4) Risks of business ………………………………………………………………………………………………….…...… 4
2. Situation of corporate group ………………………………………………………………………………………………... 11
3. Management policies ……………………………………………………..….………………………………………..…….. 11(1) Basic policy of company management …………………………..…………………………………………………..….. 11(2) Key performance index ………………………………………..……………………………………………….……..…. 11(3) Pipelines ……………………………………………………………………………………………………………….... 11(4) Medium to long-term strategy ………………………………………………………………………………….……...… 14(5) Issues to be solved by the Company …………………………………………………………………………………….. 14(6) Other important matters for the Company’s management …………………………………….…………………..…..... 16
4. Financial statements …………………………………………………………………………………………………….....… 16(1) Balance sheets …………………………………………………………………………………………………….…..… 16(2) Statements of income ………………………………………………………………………………………………..…. 18(3) Statements of changes in net assets ……………………………………………………………………..…….……...… 19(4) Statements of cash flows …………………………………………………………………………………………..…… 21(5) Events and conditions with indicate there could be substantial doubt about going concern assumption…………….…. 22(6) Significant accounting policies …………………………………………………………………………………....….... 23(7) Changes in presentation …………………………………………………………………………………..……….….… 23(8) Notes on financial statements …………………………………………………………………………………….....….. 23(Balance sheets) …………………………………………………………………………………………………...….. 23(Statements of income) …………………………………………………………………………………..……….….… 23(Statements of changes in net assets) …………………………………………………………………..………...…… 24(Statements of cash flows) ………………………………………………………………………………………..…... 25(Lease transactions) ……………………………………………………………………………………………..…..… 26(Financial instruments) …………………………………………………………………………………. …………… 30(Marketable and investment securities) ………………………………………………………………………….…… 31(Derivative transactions) ……………………………………………………………………………………………….. 32(Retirement benefits) ………………………………………………………………………………………….……..… 33(Stock options) ………………………………………………………………………………………………….…...… 33(Deferred tax accounting) ………………………………………………………………………………………….. … 47
(Equity in earnings) ……………………………………………………………………………………………….…… 47(Asset retirement obligations) ………………………………………………………………………………….....…… 47(Investment and rental properties) ………………………………………………………………………………..….… 47(Segment information) …………………………………………………………………………………………….…… 47(Related parties information) …………………………………………………………………………………..….…… 49(Per share information) …………………………………………………………………………………………….. … 49
(Significant subsequent events) ………………………………………………………………………………………… 50
5. Other ………………………………………………………………………………………………………………………… 51(1) Changes in Officers ……………………………………………………………………………………………………… 51(2) Other ………………………………………………………………………………………………………………..…… 51

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

1. Business results(1) Business results analysis(Business Results for FY 2012)
Progress in the Company’s business for FY 2012 is as follows:(i) Domestic[SyB L-0501 (the generic name: bendamustine hydrochloride, the trade name: TREAKISYM®)]
Since December 2010, the Company has been selling an anticancer drug SyB L-0501 in Japan through the business partner
Eisai Co., Ltd. (Eisai) for the indications of refractory/relapsed indolent non-Hodgkin’s lymphoma (NHL) and mantle cell
lymphoma (MCL).
The Company has been engaged in three separate clinical trials with TREAKISYM® for extended indications. For one ofthem, the Phase II clinical trials (collaborative trial in Japan and South Korea) of refractory/relapsed aggressive non-Hodgkin’s
lymphoma. The Company completed analysis and evaluation of the clinical trial data. However, based on the results of a preapplication meeting with the Pharmaceuticals and Medical Devices Agency (PMDA), we decided to suspend the application
for approval of the product we had planned to make in the fiscal year under review.
The Phase II clinical trials were conducted at 25 facilities in total in Japan and South Korea for pre-treated patients ofrefractory/relapsed aggressive non-Hodgkin’s lymphoma, with the aim of confirming the efficacy and safety of SyB L-0501
when co-administered with rituximab. Sixty-three patients were enrolled for the trials, and 59 cases were subject to analysis.
The trials showed high efficacy, resulting in a response rate of 62.7%, of which the complete remission rate was 37.3%.
Moreover, the median value of the progression free survival (PFS) period reached 200 days, indicating the possibility of
improved prognosis for patients suffering from refractory/relapsed non-Hodgkin’s lymphoma. The side effects were clinicallymanageable, and the drug proved to be applicable for the elderly.
Detailed results of the trials were presented at the American Society of Clinical Oncology (ASCO), held in Chicago in June
2012, by Dr. Michinori Ogura of Japanese Red Cross Nagoya Daini Hospital.
In addition, presentations were also made on the results of the trials by Dr. Kensei Tobinai of National Cancer Center
Hospital and several other doctors at the 74th Annual Meeting of the Japanese Society of Hematology held in Kyoto in
October 2012.
The Company will decide on the future development policy of the drug against this indication through discussions with
Eisai, our business tie-up partner.
We continued the enrollment of patients for the Phase II clinical trials for the indications of untreated indolent nonHodgkin’s lymphoma and mantle cell lymphoma, with the number of enrolled patients reaching one patient remaining to thetargeted number 67 as of the end of December 2012. As for the Phase II clinical trials for the indication of refractory/relapsed
multiple myeloma, the number of enrolled patients increased to 17, with the target number of patients being 44, as of the endof December 2012. Moreover, our notification of the clinical trial plan for domestic Phase II clinical trials for the indication ofchronic lymphocytic leukemia had been prepared and was accepted in December 2012. Furthermore, TREAKISYM® was
designated as an orphan drug (pharmaceutical for rare disease treatment) for the indication of chronic lymphocytic leukemia in
June 2012.
[SyB L-1101 (the intravenous form)/C-1101 (the oral form) (the generic name: rigosertib)]
With regard to SyB L-1101, an anticancer drug, our notification of clinical trial plan for Phase I clinical trials for theindication of refractory/relapsed myelodysplastic syndrome (MDS), a type of blood tumor, was accepted in March 2012.
Subsequently, we conducted the first patient enrollment in June 2012 and started the domestic Phase I clinical trials.
As for SyB C-1101, the oral form, our notification of clinical trial plan for Phase I clinical trials for the indication of
untreated myelodysplastic syndrome (MDS) was accepted in December 2012.
Furthermore, Onconova Therapeutics, Inc. (United States), the licenser of the drugs, announced a business tie-up with
Baxter International Inc. for the European market in September 2012.
The conclusion of this business tie-up should accelerate development and commercialization of rigosertib for the Westernmarket, and allows expectations for a heightened possibility of receiving approval as early as possible in Japan and South
Korea, where we have the development and commercialization rights, through the utilization of their clinical trial dataobtained abroad.
[SyB D-0701]-1-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

In October 2012, we completed the patient enrollment (189 cases) for Phase II clinical trial of SyB D-0701 (a transdermal
antiemetic patch) for the indication of radiotherapy-induced nausea and vomiting.
(ii) Overseas
Sales of SyB L-0501 started in Taiwan in February 2012 through InnoPharmax Inc. (Taiwan), our business partner. The
drug also sold largely as planned in Singapore and South Korea, where we sell the product through Eisai, as we do in Japan.
(iii) Fund procurement
The Company made a resolution on December 27, 2012 to issue the first unsecured convertible bond with stock acquisitionrights (total issue price: 1 billion yen) with Whiz Healthcare PE Series 1 Investment Limited Liability Partnership as theallottee and the 29th warrant (total issue price: 5.1 million yen, total issue price of stocks when issued through exercising thestock acquisition rights: 500 million yen), with the aim of accelerating development of new drug candidates and further
reinforce the pipeline. Accordingly, Whiz Healthcare PE Series 1 Investment Limited Liability Partnership completed
payment of 1,005,100 thousand yen to the Company on January 15, 2013.
(iv) Business results
As a result of the aforementioned developments, net sales totaled 1,955,178 thousand yen (a year-on-year increase of 3.9%)
for the fiscal year ended December 31, 2012, reflecting the sales of SyB L-0501 in Japan and Asian countries.
Selling, general and administrative expenses totaled 2,293,253 thousand yen (a year-on-year decrease of 15.8%), including
research and development (“R&D”) expenses of 1,438,125 thousand yen (a year-on-year decrease of 26.1%) for the accrual of
expenses associated with the clinical trials for multiple indications for SyB L-0501, clinical trials for SyB D-0701 and clinical
trials for SyB L-1101, among other things, as well as other selling, general and administrative expenses of 855,128 thousandyen (a year-on-year increase of 9.6%).
As a result, we posted operating loss of 1,700,273 thousand yen for the fiscal year ended (in contrast to operating loss of
2,066,846 thousand yen for the previous fiscal year). In addition, recording of totaling 36,516 thousand yen as non-operating
expenses, primarily comprising foreign exchange losses and bond-issue expenses, and other factors led to ordinary loss of
1,729,480 thousand yen (ordinary loss of 2,095,382 thousand yen for the previous fiscal year) and net loss of 1,733,320
thousand yen (net loss of 2,104,513 thousand yen for the previous fiscal year).
Furthermore, segment information is omitted since the Company operates a single segment of pharmaceutical businessincluding research and development of pharmaceutical drugs as well as manufacturing, marketing and other related activities.

Forecast of Business Results for FY 2013
We expect net sales of 1,927 million yen, a 1.4% decrease from the fiscal year ended. Meanwhile, for the aim of further
enhancing the enterprise value, we will advance the development of proprietary pipelines, including new indications for themainstay anticancer drug SyB L-0501.To this end, we anticipate R&D expenses of 1,408 million yen (1,438 million yen in theprevious fiscal year) and selling, general and administrative expenses of 2,356 million yen (2,293 million yen in the previous
fiscal year) including R&D expenses.
The Company’s major development plans of pipelines are as follows:<SyB L-0501> (anticancer drug)
We currently proceed with multiple clinical trials for SyB L-0501 for the extended indications and plan to apply for an
approval in Japan for the indications of untreated indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. We will also
start domestic Phase II clinical trials for the indication of untreated chronic lymphocytic leukemia. We will also consider thedevelopment of SyB L-0501 for other indications.
<SyB L-1101 / SyB C-1101> (anticancer drug)
We plan to continue domestic Phase I clinical trials of SyB L-1101 (the intravenous form) for the indication ofrefractory/relapsed myelodysplastic syndrome (MDS). We also plan to start domestic Phase I clinical trials for the indicationof untreated refractory/relapsed myelodysplastic syndrome (MDS).
<SyB D-0701> (a transdermal antiemetic patch)-2-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

We will investigate the future development policy for SyB D-0701, based on the results of the Phase II clinical trials.
As a result of these planned activities, net sales of 1,927 million yen, operating loss of 1,889 million yen, ordinary loss of
1,922 million yen, and net loss of 1,926 million yen are projected for FY 2013.
(2) Financial position analysis(Analysis of assets, liabilities, net assets, and cash flow)
Total assets as of December 31, 2012 stood at 5,502,190 thousand yen, a decrease of 1,753,904 thousand yen from theprevious fiscal year end. This was primarily due to a decrease of 1,652,522 thousand yen of marketable securities, as multiple
marketable securities matured and were transferred to cash and deposits, and the subsequent decrease in cash and deposits mainly
because of the payment of selling, general and administrative expenses. Current assets stood at 5,420,623 thousand yen, adecrease of 1,757,769 thousand yen from the previous fiscal year end, primarily reflecting a decrease of marketable securities.
Total noncurrent assets stood at 81,567 thousand yen, an increase of 3,865 thousand yen from the previous fiscal year end, due tosuch factors as the payment of leasehold deposits based on the anti-disaster office lease contract while accumulated depreciationof tangible and intangible fixed assets increasing.
Liabilities stood at 602,232 thousand yen, a decrease of 48,297 thousand yen from the previous fiscal year end, reflecting adecrease of accounts payable-other in connection with the decrease in R&D expenses.
Net assets decreased by 1,705,607 thousand yen from the previous fiscal year end to 4,899,957 thousand yen due to recording
net loss and other factors. As a result, the equity ratio decreased by 2.4 percentage points from the previous fiscal year end to
88.6%.
Cash and cash equivalents (hereinafter “cash”) stood at 4,240,022 thousand yen, a decrease of 2,070,956 thousand yen fromthe previous fiscal year end. This was mainly because of cash decrease from operating activities resulting from a decrease inaccounts payable-other and posting loss before income taxes, and of cash decrease from investing activities due to purchase ofproperty, plant and equipment, in spite of a slight decrease in accounts receivable-trade and inventories.
Cash flows from each activity and its factors for this fiscal year end are as follows:(Cash Flow from Operating Activities)
Cash flow from operating activities showed a decrease of 1,648,808 thousand yen due to such decreasing factors as net loss
before tax of 1,729,520 thousand yen recorded and a decrease of accounts payable by 82,105 thousand yen, despite suchincreasing factors as a decrease of inventories by 42,895 thousand yen, a decrease of consumption tax receivable by 30,076
thousand yen, a decrease of advances by 25,552 thousand yen and an increase in trade payable by 20,814 thousand yen.
(Cash Flow from Investing Activities)
Cash flows from investing activities showed a decrease of 410,563 thousand yen mainly due to a cash decrease of 100,000
thousand yen for the purchase of marketable securities and 300,000 thausand yen for increae in time deposits.
(Cash Flow from Financing Activities)
Cash flows from finacing activities showed a decrease of 719 thousand yen due to a decrease of lease obligations.

-3-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Development of index related to cash flow)
4th Term

5th Term

6th Term

7th Term

8th Term

Fiscal year ended

Fiscal year ended

Fiscal year ended

Fiscal year ended

Fiscal year ended

December 2008

December 2009

December 2010

December 2011

December 2012

87.0

95.1

95.8

91.0

88.6

market value basis (%)

―

―

―

126.0

104.3

Debt redemption period

―

―

―

―

―

―

―

―

―

―

Equity ratio (%)
Equity ratio on a fair

(years)Interest coverage ratio

Equity ratio: Equity (net assets excluding subscription rights to shares) /total assets
Equity ratio on a fair market value basis: total market value of common stock/total assets
Debt redemption period: Interest-bearing debt/cash flow from operating activities
Interest coverage ratio: cash flow from operating activities/interest payment(Notes) 1. Equity ratio on a fair market value basis is not shown until the 6th term and is shown from the 7th term.
2. Total market value calculated based on the number of shares issued excluding treasury stocks.
3. Debt redemption period and interest coverage ratio are not available for the 5th Term and after because of negative
cash flow from operating activities.
2. Debt redemption period and interest coverage ratio are not available for the 4th Term because of no interest-bearing
debt and interest expense.
(3) Basic policy for profit distribution and dividends for FY 2012 and 2013
Since the foundation of SymBio, dividends have not been distributed.
Although SymBio started booking product sales, the company develops pharmaceutical drugs and continues to use funds fordevelopment activities. Therefore, it is our policy to attempt to gain retained earnings, not to distribute profit dividends, andpreference to retain funds for sustainable development activities. However, we recognize that the return of profit to stockholders
is an important management issue and will consider profit distribution based on future business performance and financial
condition.
The articles of incorporation provide that the Company can pay interim dividend based on a corporate resolution by Board of
Directors on June 30 every year as the record date. The Company can also make a distribution of surplus by designating a record
date in addition to year-end and interim dividends. Decision making body is board of directors for interim dividend, shareholders'meeting for year-end dividend.
(4) Risks of business
Described below are major issues that may lead to potential risks in the Company's business activities. Issues that are notnecessarily considered significant by the Company are also disclosed, in view of our commitment to make active information
disclosure to investors and shareholders as these issues may carry weight in making investment decisions or in understanding ourbusiness activities. The Company is fully aware of the potential of these risks and will exert its utmost effort to prevent such risks
from substantiating, but should they substantiate, we intend to take full appropriate action. However, we consider that investment
decision regarding our stocks should be made by carefully evaluating the following matters, as well as other matters mentioned
in other sections of this document. We would add that the following descriptions do not purport to cover all possible risks
associated with investment in our stocks. The future perspectives mentioned below reflect our understanding of our businesscircumstances as of the date of publication of this document.
(i) Risks associated with pharmaceutical development in general
SymBio's main business is to in-license drug development candidate compounds created by pharmaceutical companies and bio
ventures, and to develop them into pharmaceutical products. The R&D field of pharmaceuticals is replete with strong
competition including pharmaceutical giants. What is more, specialty pharmaceutical companies such as SymBio try to emulate
each other in quality and speed within the sector. The process from development to manufacture and marketing involves many

-4-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

regulatory hurdles, necessitating a vast amount of capital input over a long period of time in business operations. Their future
prospects involve uncertainty and these risk factors are associated with the Company’s present and future business activities.
(a) Uncertainty involved in pharmaceutical development
Generally speaking, the pharmaceutical development process up to the market launch of a drug requires a vast amount ofexpenditure over a long period. The probability of success is by no means high. In every stage of development, it is not
infrequent for a decision to be made to halt or delay progress. In pharmaceutical development, the different stages ofdevelopment have to be conducted in phases, and in each phase a decision is made on whether the development should
continue. Therefore, it is not rare to see a decision to stop a development in mid-process. The probability is low for adevelopment progressing successfully and for a product coming on stream. Even after a product is successfully developed andlaunched in the market, there remains a risk that the approval gets cancelled because of inefficacy or side effects should
serious side effects prove to have the potential to increase damage to health (for details, refer to “(f) risk associated with side
effects”), or should the efficacy fail to be recognized by the re-evaluation of efficacy and safety, conducted either on a regularor temporary basis, in light of the current academic standards of medicine and pharmaceuticals at the time of re-evaluation. To
reduce and spread these risks, the Company aims to possess several pipelines and endeavors to prioritize insofar as possible
the in-licensing of drug candidates with confirmed POC (note) on human subjects. Yet, for small specialty pharmaceuticalcompanies such as SymBio, the impact is huge if a single candidate compound is removed from the pipeline. This could havea significant effect on our financial position, business performance, and cash flow.
(note) POC (Proof of Concept) means confirming the efficacy and safety of a new drug candidate compound throughclinical trials and verifying the appropriateness of its concept.
(b) Uncertainty of income
In order to raise income from the products we are developing, we need to succeed in all the stages of drug candidate
development, namely obtaining approval from regulatory authorities, manufacture and marketing either on our own or inpartnership with a third party. However, we may not necessarily succeed in these activities, or even if we do succeed, we may
not be able to ensure the sufficient profitability needed in continuing our business. We currently hold four items in thepipeline. SyB L-0501, an anticancer drug, gained an approval for manufacturing and commercializing in Japan on October 27,
2010, indicated for the treatment of refractory/relapsed indolent non-Hodgkin's lymphoma as well as refractory/relapsed
mantle cell lymphoma. As additional indications, we have completed Phase II clinical trials for refractory/relapsed aggressive
non-Hodgkin’s lymphoma, and are conducting Phase II clinical trials for the indications of untreated indolent non-Hodgkin's
lymphoma and untreated mantle cell lymphoma, and for refractory/relapsed multiple myeloma. SyB D-0701, a transdermal
antiemetic patch, has completed the patient enrollement for Phase II clinical trials. SyB L-1101 (the intravenous form)/SyB C1101 (the oral form), anticancer drugs in-licensed in July 2011, are undergoing Phase I clinical trials in the intravenous form
indicated for the treatment of myelodysplastic syndrome (MDS), and Phase I clinical trials of the drugs are planned to start for
the indication of untreated myelodysplastic syndrome (MDS). We are promoting the development of these compounds, aiming
to successfully market the end products to obtain income. In some cases, we may consider entering into alliance with otherpharmaceutical companies in development and marketing so as to expedite the in-flow of income. Notwithstanding our effort,
these pipeline compounds will take a considerable amount of time before they reach the market. There is no guarantee thatthey will make it onto the market as viable products or that an alliance agreement can be signed with other pharmaceuticalcompanies. We are of the opinion that the selection of indications and the methods of alliance and marketing so far identified
promise sufficient future profitability, considering the market size and marketing performance of approved drugs. However,should we prove to be wrong in the assessment, or should there be any change in the conditions on which the assessment isbased and we cannot promptly adjust to the changes, there may be a significant impact on our financial position, businessperformance, and cash flow.
(c) Uncertainly in legislations and regulations requiring compliance and health insurance system
The pharmaceutical industry, SymBio‘s business field, is subject to various regulatory restrictions imposed by thepharmaceutical laws and administrative guidance as well as other relevant legislations of respective countries in all aspects ofbusiness operations, namely, research, development, manufacture and marketing. We formulate our business plans inaccordance with the pharmaceutical laws and other current legislative regulations and with the health insurance system
together with the drug pricing developments that emerge from these legislations. Notwithstanding, there is a possibility thatthese regulations, systems and pricing will change before the products that we are developing reach the market. If any majorchange does occur, there may be a significant impact on our financial position, business performance, and cash flow.

-5-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(d) Risk concerning development and marketing overseas
We conduct pharmaceutical business in Asia, not limited to Japan, where we anticipate growth of healthcare needs andposition as the strategic business domain. In overseas markets similarly to in Japan, the pharmaceutical development andmarketing generally require a vast amount of expenditure and are associated with business risks. To reduce investment
expenditure and spread business risks, we out-license the development and marketing of some of our developed drugs
overseas to pharmaceutical and other companies. When we out-licenses the rights we possess, we select a licensee company
after careful due diligence and continue monitoring as appropriate. The development and sales of out-licensed products are
subject to business conditions of the licensee company or any changes in regulatory and competitive environments in
respective countries and may fall below the original expectations, resulting in milestone revenue and royalty income generated
below our plan. In such cases, there may be an impact on our financial position, business performance, and cash flow.
(e) Competition in the pharmaceutical industry
The pharmaceutical industry is an intensely competitive sector. A large number of both Japanese and foreign
pharmaceutical companies and research institutions including giant multinational pharmaceuticals compete in the arena.
Technological innovation is progressing rapidly. Many competitors have comparative advantage over us in technology,
marketing and financial position. Thus these companies may more efficiently produce and sell competitor products of greater
effectiveness to our developed products. This means that what transpires in the competition we conduct with these competitors
in development, manufacturing and marketing operations may have a significant impact on our financial position, businessperformance, and cash flow.
(f) Risk associated with side effects
Unexpected side effects may occur from the use of pharmaceutical products, from their clinical trial stage to post-marketingstage. When serious and unexpected side effects are developed, compensation claims may arise, or depending on the situation,
there is the risk of a delay in clinical trials or even discontinuation of product development. In case such side effects could leadto further damage to health, there is the risk for the cancellation of approval or the discontinuation of sales. Regarding
compensation claims, we have in place the liability insurance necessary to minimize the financial damage when such claims
arise. However, it does not exclude the possibility that the compensation award exceeds the amount insured. If that happens,there may be a significant impact on our financial position, business performance, and cash flow.
(g) Product liability
The development and manufacture of pharmaceutical products involve product liability risk. If in future, any products that
we have developed cause damage to health or any inappropriate matters are discovered in clinical trials, manufacture, sales ormarketing, we will be subject to product liability. This may have a significant impact on our financial position, businessperformance, and cash flow. Indeed, if a product liability compensation suit is filed against us, our corporate image will bedamaged, leading to loss of confidence in us and our drugs, which may have an impact on our business.
(ii) Risk in operating our business(a) Risk concerning business model
SymBio does not own its research and manufacturing facilities. We mainly target orphan drugs in oncology, hematology
and autoimmune diseases, in-licensing from pharmaceutical companies and bio ventures drug candidates mostly with POC
confirmed on human subjects and developing and marketing them as pharmaceutical products for the Japanese and Asianmarkets (China, South Korea, Taiwan and Singapore, etc.). We adopt the business model to raise income and profit fromdoing so. In developing the pipeline and marketing, we plan to engage in alliances with other pharmaceutical companies.
However, there is no guarantee that we can continuously in-license drug candidate compounds that satisfy our criteria andsecure these partner companies. In addition, as we mainly target orphan drugs for in-licensing, we may not be able to generate
the expected sales turnover. In such cases, there may be an impact on our financial position, business performance, and cash
flow. What is more, the competition surrounding the pharmaceutical sector and changes in SymBio's financial position may
force us to revise our business model. Should this occur, there may be a significant impact on our business.
(b) Dependency on a specific customer
As a specialty pharmaceutical company without production facilities, SymBio needs to depend on supply of products fromother companies when conducting the clinical trials of products under development and in post-marketing sales. Given this-6-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

fact, the financial position and production conditions of the product supplier may have a significant impact on our financial
position, business performance, and cash flow. In pipeline development and marketing, our current business plan is focused on
forming alliances with pharmaceutical companies. However, if the partner company's management condition deteriorates
drastically or if its management policies change, which are matters beyond our control, our initial business plan may not berealized. Also, if any breach of contract occurs that necessitate the termination of the contract as stipulated by the contract, thealliance may end before the agreed term. In such cases, there may be a significant impact on our financial position, businessperformance, and cash flow. Normally, in alliance contracts with partner companies, expected revenues of specialty
pharmaceutical companies such as SymBio, to be gained before the products reach the market will be a lump sum uponsigning the contract, funding for co-development and milestone payment. Of these, the milestone payment is an extremely
unstable and unpredictable income as it is based on the attainment of predefined results. If development progress is delayed,
there may be a significant impact on our financial position, business performance, and cash flow.
(c) Risk concerning intellectual property rights
In our drug development activities, we make use of various intellectual property rights. The use of these rights basically has
been granted from other companies such as pharmaceuticals and ventures. However, the possibility remains that our inlicensed candidate compound does not succeed in the pending patent application made by the in-licensing partner. Moreover,
it is difficult to completely avoid a third party creating an intellectual property right that supersedes the intellectual property
right to which we have consent of use. These situations could lead to a significant impact on our financial position, businessperformance, and cash flow. To date, no lawsuit has been filed by a third party against us concerning intellectual property
rights, including patents in connection with our product developments. However, in June 2009, an overseas pharmaceuticalcompany issued a written warning to us. The company demanded that there be no infringement of the patent in Japan of a
product owned by this company. In light of the advice from patent attorneys and lawyers, we believe that the claim being
made by the overseas company is groundless. Meanwhile, we have received no other request from the said company sinceJune 2009 and therefore, our understanding is that we are not in dispute. Should a dispute arise with this company, there may
be a significant impact on our financial position, business performance, and cash flow. When in-licensing a product, we takeadvice from lawyers and conduct a thorough due diligence investigation through patent firms in order to reduce suchintellectual property risks. Nevertheless, it is difficult to realize full protection from the occurrence of intellectual property
right disputes involving the infringement of third-party rights, and these may have a significant impact on our financial
position, business performance, and cash flow. The candidate compounds that we in-license are not necessarily protected bypatent. On the other hand, even if our candidate compound is not protected by patent, the assignment of the compound forreview by the regulatory authorities would virtually restrict the entry of generic drugs during the review period, realizing themonopolistic protection for a certain period of time.
(d) Data protection
To reduce the risk of significant confidential information relating to pipeline development and other business activities fromleaking outside the company, SymBio engages in rigorous data protection. We require directors, Scientific Advisory Board(SAB) members, outsourcing partners, and other business partners to sign confidentiality agreements. Even with theagreement in place, directors, SAB members, outsourcing partners and other business partners may not adhere toconfidentiality, and should this occur, significant confidential information may be divulged elsewhere, which may impact ourbusiness, financial position, business performance, and cash flow.
(e) Risk concerning important contracts
If any contracts that might have significant impact on conducting our business operations are terminated due to its reachingfull term, being cancelled or for any other reason, there may be a significant impact on our financial condition, businessperformance, and cash flow.
(iii) Risk associated with organization(a) Risk of being a young company
SymBio is a young company founded in March 2005.Since inception, we have engaged in in-licensing activities of drug
development candidate compounds. We built up the pharmaceutical development business from scratch and recorded income
from product sales in August 2010 for the first time in our history. There is a possibility that business issues that we have notever encountered arise in future. At the moment, however, it is difficult to predict any changes in the external environmental-7-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

factors that may affect our business results. Therefore, we consider our business results for the past years to be inadequate
reference material for passing an objective judgment on whether or not our company can continue to grow.
(b) Risk of being a small corporation
SymBio uses contract research organizations (CRO) in conducting R&D, thereby forming a development framework
requiring relatively small staff numbers. With progress in the development of pipeline already in place and with new pipelinesof new candidate compounds coming on stream, we plan to increase its human resources in R&D. However, for whateverreason, should an alliance with a CRO become terminated or should we fail to secure the planned number of staff or should theexisting staff decide to leave, our business operations may be hampered, leading to a possible impact on our financial position,business performance, and cash flow.
(c) Dependency on a specific person
Mr. Fuminori Yoshida, the Representative Director, founding President and CEO, has played a key role since SymBio’s
foundation in the implementation and execution of all operations in the company business management. Thus, in the event that
Mr. Yoshida cannot continue to perform his corporate responsibilities for some unforeseen reasons, it will have a significant
impact on our business operations.
(d) The Scientific Advisory Board (SAB)The Scientific Advisory Board (SAB) is an advisory panel to the president on the in-licensing evaluation of new drugcandidates. We invite members of the panel from clinicians and scientists engaged in basic research who we regard as having
excellent track records and experience. The SAB meets two or three times a year to engage in active discussion and debate,with each member giving his/her specialist perspective so that a good risk-balanced portfolio can be created from among thevast volume of drug candidates gathered from the worldwide, with due consideration of healthcare needs and profitability. We
will continue in our effort to acquire members of excellence for the SAB. However, if difficulty should arise in procuring
members, for reasons such as the cancellation of contract with existing members, ending of the term of office or refusal ofrenewal, or should a brain drain occur, there may be an impact on our in-licensing of drug candidates.
(ix) Business Results(a) Business performance in past years
SymBio's key business indicators are given below
Term

4th Term

5th Term

6th Term

7th Term

8th Term

Fiscal Year Ended

December 2008

December 2009

December 2010

December 2011

December 2012

1,630,029

1,191,127

1,449,972

1,882,521

1,955,178

Operating income (loss)(thousand yen)

132,859(208,027)(612,793)(2,066,846)(1,700,273)

Ordinary income (loss)(thousand yen)

24,169(214,072)(638,375)(2,095,382)(1,729,480)

Net sales (thousandyen)

SymBio’s net sales up until the 5th Term consisted only of income from alliance contracts (e.g. contract agreement lumpsum, milestone payment). From the 6th Term, we have recorded sales deriving from the sale of products. To date, with the
exception of the 4th Term, the total R&D expenses and other general administrative expenses exceeded our income, resulting
in the posting of operating loss, ordinary loss and net loss. For this reason, we do not consider the financial statements andindicators for past years to provide adequate reference data in making timely comparisons in business performance and in
forecasting our future business performance.

-8-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(b) Expected Increase in R&D Expenditure
SymBio's R&D expenses for the past five fiscal years are given below
Term

4th Term

5th Term

6th Term

7th Term

8th Term

Fiscal Year Ended

December 2008

December 2009

December 2010

December 2011

December 2012

868,241

816,501

1,118,182

1,945,029

1,438,125

R&D expenses (thousandyen)

SymBio intends to further continue R&D activities, which would mean an increase of the cumulative loss for theforeseeable future. With future increases in the product sales revenue from more additional indications of SyB L-0501 and in
the income from alliances with pharmaceutical companies, we intend to improve our business performance as soon as
possible; however, there is no guarantee that our assumptions will materialize and swift performance improvement seen.
(c) Negative balance of retained earnings brought forward
SymBio is a specialty pharmaceutical company. Until the products under development at the clinical stage reach the market
so that we can earn stable income through product sales and royalty income, we will post a huge up-front outlay of R&D
expenditure. Due to this, except 4th term (2008), we have posted net current losses since our foundation. At the end of 8thTerm, the year ended December 31, 2012, we recorded negative balance of 7,146,411 thousand yen as retained earnings
carried forward.
We intend to become a profitable business entity as early as possible by advancing our quality clinical programs in a rapid,
precise and efficient manner as planned. However, the possibility still exists that profits may not be generated at the time
initially planned. Should our business fail to develop as planned and net profits are not generated, we face the possibility of aconsiderable delay in our negative retained earnings carried forward turning positive.
(d) Fund-raising
The nature of SymBio's specialty pharmaceutical business means that the Company will require huge R&D funding. If ourbusiness plan does not take shape as planned and we suffer a shortfall in funding, we will endeavor to procure funds bychanging our strategic alliances, securing new alliance contracts or issuing new stocks. However, if we fail to generate funds
exactly when they are required, there may be a serious doubt cast over the continuation of our business operations.
(e) Net operating loss carried forward on tax
Net operating loss carried forward on tax exists this year end. For this reason, we are not subject to corporate tax, local
inhabitant tax and local enterprise tax at the standard rates and we expect this to continue for several terms into the future.
However, if our business performance makes a good progress in future due to favorable business development, net
operating loss carried forward may be removed earlier than anticipated and no longer be applied to the deduction of taxable
income. Should this situation occur, we would become liable for the payments of corporate tax, local inhabitant tax and local
enterprise tax at standard rates, which may have an impact on net profit/loss and cash flow currently planned.
(v) Other Risks(a) Profit distribution to stockholders
Since the foundation of SymBio, dividends have not been distributed. We are currently at a business stage of still making
up-front investment into the development of pharmaceutical drugs and we continue to prioritize the use of funds forstrengthening our financial position and for continued R&D activities. Thus, we have at present no plans for making dividend
payout. However, we recognize that the return of profit to stockholders is an important management issue and will consider
profit distribution based on future business performance and financial condition.
(b) Procurement of funds
As we rapidly expand our business, we expect to see an increase in our development funding requirement. One of ouroptions for procuring funds is to issue new stocks. If we do so, the number of our outstanding stock will increase, potentiallydiluting the value per share of our stock.

-9-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(c) Stock value dilution by execution of stock acquisition rights
We adopt the stock option plan in order to motivate and encourage higher business performance of board directors,
employees, and collaborators, and to attract human resources of excellence. In accordance with the Commercial Code of 1890
Article 280-19, 280-20 and 280-21, and Companies Act Article 236, 238, and 239, stock acquisition rights are granted toboard directors and employees.
Moreover, the Company made a resolution at the Board of Directors meeting held on December 27, 2012 to issue the 1st
convertible bond with stock acquisition rights (total issue price: 1 billion yen) by way of third-party allotment and the stock
option (total issue price: 5.1 million yen, total issue price of stocks when issued through exercising the stock acquisition rights:
500 million yen). The proceeds from the issuance were paid in on January 15, 2013.
As of the date of publication of this document, the number of the above-mentioned stock acquisition rights and theconvertible bond with stock acquisition rights (hereinafter, number of potential shares) totals 5,197,343 shares and comprises
approximately 19.7 % of the total number of outstanding shares and potential shares added together.
There is the possibility that stock value per share for the company will be diluted if these potential shares are exercised in
the future. To attract talent, the Company may continue to offer similar incentives. This means that if these stock acquisitionrights are exercised in future, the stock value per share of the company may be diluted.
(d) Legal risk pertaining to unregistered offering of stock acquisition rights in the past
The Company has granted stock acquisition rights under the stock option plan as long-term incentives for board directors
and employees as well as collaborators since the foundation in March 2005.
Stock acquisition rights have been issued since the inception of plan paying special attention to a provision of Securities andExchange Law of 1948 that board directors and employees are excluded from the calculation of number of persons receiving
minority private offering. However, even after Order for Enforcement of the Financial Instruments and Exchange Act Article
2-12 was no longer exempted (the article had purported to exempt the application of the provision that required the exclusionof directors/officers and employees from the calculation of persons receiving small private offerings in case stock acquisitionrights were granted to persons other than directors/officers and employees) due to the amendment of Guidance for Corporate
Information and Related Disclosure in response to the revision of Financial Instrument and Exchange Act in September 2007,
we had continued to issue stock acquisition rights in accordance with the provisions of Securities and Exchange Act 1948 dueto the malfunction of internal organizations to collect information regarding revision of laws and ordinances and assess theirimplications to the Company.
In consequence, it came to light that we had not duly submitted Securities Registration Forms for the stock acquisitionrights it had issued in October 2008, March 2009, and March 2010 despite there being legal obligations to do so as the numberof persons receiving offers had exceeded 50, making them unregistered offerings prohibited under the laws.
Immediately upon discovery of this lapse, we reported the fact to the Kanto Local Finances Bureau and launched a thoroughenquiry into how and why such omission arose, and swiftly submitted the legally required disclosure documents in August
2010. At the date of publication of this document, we have duly filed all the required disclosures.
Furthermore, based on in-house findings concurrently obtained regarding the cause of omission and advice received fromexternal experts, measures to prevent recurrence are formulated and put strictly in effect focusing on the following five
objectives: 1. Re-education regarding compliance at the whole company level, 2. Creation of compliance mechanism andinternal organization reinforcement, 3. Reinforcement of compliance committee functions, 4. Reinforcement of relations withand active use of external experts, 5. Reinforcement of a system of checks by the board of auditors and internal audit office
We have not received any surcharge payment order related to this incident at the date of publication of this document.
Should we receive any surcharge payment order, however, it may have a significant impact on our financial position, businessperformance, and cash flow.
(e) Stock holding by venture capitalIn general, venture capitals and investment partnerships own shares for the purpose of realizing capital gains by sellingshares after the IPO. There is the possibility that venture capitals and investment partnerships that own our shares may sell all
or a portion of our shares they own, and should it occur, it may have an impact on the market price of our share.
(f) Risk associated with natural disasters- 10 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

If any disasters (earthquake, typhoon, fire, etc.) and plague occur in our geographic business domains, which lead to theoccurrence of human and material damage, or suspension and delay in business, fall in social credibility and compensation
issues may have an impact on our financial position, business performance, and cash flow.

2. Situation of corporate group
None to be reported.

3. Management policies(1) Basic policy of company management
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida, who previously served concurrently
as Corporate VP of Amgen Ltd.(United States) and President of Amgen Japan (currently Takeda Bio Development Center
Limited) for 12 years since its founding stage.
We aim to achieve social and management responsibilities by responding to unmet medical needs with guiding principle ofmutual harmony, spinning an intricate symbiotic relationship between patients, physicians, scientists, regulators and investors.
We regard underserved therapeutic areas with extremely significant medical needs as a business opportunity and focus on theareas of oncology, hematology, and autoimmune diseases where high entry barriers exist due to the high degree of specialization
required. In this sense, we are the first specialty pharmaceutical company in Japan. Rather than exploring blockbuster new drugs(those with the sales of more than 100 billion yen), we channel our resources into the development of new drugs specializing inoncology, hematology, and autoimmune diseases, where medical needs are outstanding though with the limited market size.
Holding multiple promising drugs and drug candidates in these areas will enable us to build the solid portfolio of pipelines andcontinue our business sustainably.
(2) Key performance index
We are of the opinion that, in order to enhance our enterprise value as a specialty pharmaceutical company, it is inevitable tocontinually in-license candidate drugs under development and proceed with the development to place the products on the market,
and establish the sale and support system. To this end, we intend to aggressively make an ongoing investment of management
resources into R&D activities.
We have several years product sales record of SyB L-0501 in Japan and Asian countries. However, the product sales have notgenerated revenue enough to cover the aforementioned upfront investments at this moment and net profit has yet to be realized.
We continuously seek the early realization of a system to secure the stable profitability by promoting TREAKISYM® incollaboration with Eisai, actively adding new indications for SyB L-0501, and developing and acquiring an approval for otherproducts in the pipeline.
(3) Pipeline
SymBio currently has four pipeline products, SyB L-0501, SyB L-1101, SyB C-1101 and SyB D-0701.We will continue to inlicense new candidate drugs so as to expand and build the pipeline portfolio with the balanced risk-return trade-off.
(i) SyB L-0501
Bendamustine hydrochloride (the generic name), the active pharmaceutical ingredient of SyB L-0501, is an anticancer drugthat has been in use for a number of years in Germany under the trade name of Ribomustin for the treatment of non-Hodgkin's
lymphoma (note 1), multiple myeloma, and chronic lymphocytic leukemia. We have elected to in-license this product because
there is currently no effective medication for the indications of refractory/relapsed indolent non-Hodgkin’s lymphoma andmantle cell lymphoma. These are precisely underserved therapeutic areas aligned with our corporate missions and also fallwithin one of our targeted therapeutic fields (hematologic cancer). Astellas Deutschland GmbH is the worldwide licensor of
bendamustine hydrochloride. In North America, Cephalon, Inc. (United States) is licensed from Astellas Deutschland GmbHand obtained approvals from Food and Drug Administration (FDA) in the United States to use the drug for the treatment ofchronic lymphocytic leukemia and refractory B-cell non-Hodgkin’s lymphoma in March 2008 and October 2008, respectively.
Mundipharma International Corporation Limited (United Kingdom) and Jenssen-cilag (United Kingdom) are also licensed
from Astellas Deutschland GmbH and have the exclusive rights for development and marketing for Europe and other regions,
respectively. Meanwhile, SymBio is licensed from Astellas Deutschland GmbH and has the exclusive rights for development
and marketing for Japan, China (including Hong Kong), South Korea and Singapore. In Japan, the drug received a- 11 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

manufacture and marketing approval with the indications of refractory/relapsed indolent non-Hodgkin’s lymphoma and mantle
cell lymphoma on October 27, 2010 and came into market under the trade name of TREAKISYM® on December 10, 2010.
In addition, the Company is working on the development for refractory/relapsed aggressive non-Hodgkin’s lymphoma,
untreated indolent non-Hodgkin’s lymphoma, untreated mantle cell lymphoma, refractory/relapsed multiple myeloma anduntreated chronic lymphocytic leukemia to add new indications. We intend to maximize the enterprise value of bendamustineby further promoting life cycle management. Eisai Co., Ltd. has the rights for joint development and exclusive marketing
under the contract with us and sells the product in Japan.
In Asia, SyB L-0501 received the approval for the indication of indolent non-Hodgkin’s lymphoma and chronic
lymphocytic leukemia in Hong Kong in December 2009.In Hong Kong, Cephalon, Inc. has the exclusive rights fordevelopment and marketing and sells the drug. SyB L-0501 received the approval for the indications of indolent nonHodgkin’s lymphoma and chronic lymphocytic leukemia in Singapore in January 2010.
In South Korea and Singapore, Eisai has the exclusive rights for development and marketing under the contract with us. In
Singapore, Eisai started to sell the product in September 2010 after receiving the approval. In South Korea, SyB L-0501
received the approval for the indications of chronic lymphocytic leukemia and multiple myeloma in May 2011 and Eisai
started to sell the drug in October 2011.
Else, Cephalon, our business partner, is conducting the clinical trials in China and our business partner InnoPharmax Inc.
(Taiwan) received the approval on October 18, 2011 in Taiwan for SyB L-0501, starting to sell the product in February 2012.
At the American Society of Hematology (ASH) held in December 2009, Professor Mathias J. Rummel of University
Hospital in Giessen (Germany) reported that the combination therapy with bendamustine and rituximab (note 2) causes fewerside effects and is more efficacious than R-CHOP therapy (note 3) currently in use as the standard treatment of indolent nonHodgkin’s lymphoma as a result of the comparative study of untreated patients.
In this study (the Phase III clinical trials conducted in Germany), 549 untreated patients (note 4) of malignant non-Hodgkin’s
lymphoma and mantle cell lymphoma were grouped at random into those undergoing the combination therapy of
bendamustine and rituximab and those undergoing R-CHOP therapy, and the efficacy, safety and progression free survival(PFS) period (note 5) were comparatively considered between the two groups. The analysis of 513 valid cases exhibited that themedian of progress free survival period (the primary evaluation item) was 54.9 months in the group with bendamustine andrituximab, prolonged by more than 20 months than 34.8 months in the R-CHOP group, which was a statistically significant
difference. As for side effects, statistical significance was exhibited for hemotoxin, the use of G-CSF (note 6), and hair loss.
Professor Rummel concluded that the combination therapy of bendamustine and rituximab could be the first-line therapy forsuch indolent non-Hodgkin’s lymphoma as follicular lymphoma and mantle cell lymphoma.
On December 22, 2009, approximately three weeks after the announcement by Professor Rummel at ASH, U.S. National
Comprehensive Cancer Network revised Clinical Practice Guidelines in Oncology and the combination therapy of
bendamustine and rituximab was listed in the guideline as a recommended first-choice drug for untreated patients of follicularlymphoma (indolent non-Hodgkin’s lymphoma) and mantle cell lymphoma.
(Note 1) Non-Hodgkin’s lymphoma (NHL) is a cancer of lymphatic system in which lymphocytes develop malignant growths
other than Hodgkin’s lymphoma. The majority of Japanese patients are suffering from NHL.
Antibody therapy with rituximab administered as first-line drug is the standard treatment for NHL. However, there is currently
no established therapy for failed or relapsed cases.
(Note 2) Rituximab is a monoclonal antibody against the protein CD20 used in the treatment of CD20-positive B-cell nonHodgkin’s lymphoma. In Japan, Chugai Pharmaceutical Co., Ltd. is the original seller and Zenyaku Kyogyo Co., Ltd.
manufactures and sells Rituxan® Injection 10mg/mL.
(Note 3) R-CHOP therapy denotes the combination therapy with rituximab, cyclophosphamide, doxorubicin, vincristine andprednisolone.
(Note 4) Untreated patients are those who have never been treated in the past and receive the treatment for the first time for theindication.
(Note 5) Progression free survival (PFS) period is the length of time during which the patients survive free of diseaseprogression.
(Note 6) G-CSF is the abbreviation for granulocyte-colony stimulating factor.
(ii) SyB L-1101/C-1101
SyB L-1101 (the intravenous form)/C-1101 (the oral from) (the generic name: rigosertib) is a multi-kinase inhibitor (note 7)with a unique mode of action against cancer. It is presently under development by Onconova Therapeutics in the United States- 12 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012and Europe for the indications of myelodysplastic syndromes (MDS), pancreatic cancer and ovarian cancer. Phase III clinical
trials are underway for the indication of refractory/relapsed MDS (administered by intravenous injection), the most advancedstage development of rigosertib, with an orphan drug designation by Food and Drug Administration in the United States in2009 and special protocol assessment (SPA) (note 8) for Phase III trial design as well.
In addition to the aforementioned advancements, an oral formulation of rigosertib is under development by Onconova
Therapeutics and Phase II clinical trials are underway for myelodysplastic syndromes (MDS) as the indication. Phase I clinical
trials have been completed in solid tumors with the initiation of the Phase II/III combination clinical trials in pancreatic cancer
and Phase II clinical trials in ovarian cancer.
SymBio signed the license agreement with Onconova Therapeutics in July 2011, for the exclusive right to develop andcommercialize rigosertib for Japan and South Korea. Based on this agreement, we plan to advance the development of theintravenous form of rigosertib in refractory/relapsed MDS, for which late stage development is conducted in the United Satesand Europe, and subsequently in the oral form in untreated MDS. MDS represent a group of hematologic tumors with theincreasing number of patients and commonly affects the elderly. MDS are relapsed diseases with a higher likelihood ofdeveloping leukemia. Effective medication has not been found especially for refractory/relapsed MDS, creating an
underserved therapeutic area.
We will continue the development for the indication of solid tumor as well as MDS. We plan to develop the treatment
methods that are well tolerated by patients and in compliance with relevant laws and regulations by appropriately alternating
the developments of the intravenous and oral forms.
(Note 7) Multi-kinase inhibitors impede the growth, proliferation and metastasis of cancer cells, thereby eradicating them.
(Note 8) SPA is a declaration from FDA after the end of Phase II clinical trials that an uncompleted Phase III clinical trial’s
design, indications, clinical endpoints, valuation items, and statistical analyses agreed upon at the pre-Phase III meeting areacceptable for FDA approval. New drug licensing application utilizing this scheme facilitates the evaluation and approval by
FDA and enhances the possibility of secure product launch in the market because FDA already completes the considerationsof the contents of Phase III clinical trials in advance.
(iii) SyB D-0701
SyB D-0701 is a sustained-release transdermal antiemetic patch containing granisetron and used to relieve nausea andvomiting (note 9) associated with cancer chemotherapy and radiotherapy. SyB D-0701 has an antiemetic effect that is sustainedfor 5 days and improves the effectiveness of treatment of patients undergoing chemotherapy and radiotherapy.
Thus, SyB D-0701 is expected to bring significant benefits to patients as well as health professionals involved as supportive
care (note 10) for cancer chemotherapy and radiotherapy outpatients as cancer prevalence continues to rise in future, and to
improve overall QOL (Quality of Life) of patients.
SymBio obtained from Abeille Pharmaceuticals, Inc. (United States) the exclusive right for development andcommercialization for Japan, China (including Hong Kong), South Korea, Singapore and Taiwan and proceeds with thedevelopment.
We started Phase II clinical trials in December 2010 with the intention to develop a drug for radiotherapy-induced nausea
and vomiting to begin with for which significant unmet medical needs exist due to the lack of effective medication. Patient
enrollment for the phase II trials was completed in October 2012. We will conduct detailed analyses to investigate the future
direction of the development.
(Note 9) Approximately 30% to 90% of patients experience nausea and vomiting associated with cancer chemotherapy andradiotherapy. These symptoms are some of the most painful side effects for patients. Persistent nausea and vomiting may leadto dehydration, electrolyte imbalance, and nutrient deprivation. They may also significantly influence the effectiveness ofcancer treatment due to loss of appetite or aggravated physical and mental condition of patients. Limiting nausea and vomiting
to the minimum is a key to improve overall compliance and leads the treatment to success. Vomiting is divided into three maincategories:
1. Acute
Vomiting develops within 24 hours of dosage of anticancer drug, usually starting within 1 or 2 hours.
2. Delayed
Vomiting develops from 24 to 120 hours after dosage of anticancer drug, and persists for several days.
3. Anticipatory
Vomiting usually develops on the day prior to dosage of anticancer drug.

- 13 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Note 10) Supportive care for cancer chemotherapy consists of the treatment of cancer-induced symptoms and complications
and the control of side effects of chemotherapy and radiotherapy, and also includes mental supports for patients. It assumes
considerable significant in cancer treatment to control cancer-induced pains and nausea and vomiting associated withchemotherapy and radiotherapy.

(4) Mid-Term/Long Term strategy
SymBio is pursuing primarily the following five strategies in order to achieve Long Range Plan (LRP).
(i) De-risking by post-POC strategy
We in-license drug candidates for which POC (proof of concept) is already confirmed on human subjects in principles.
Accordingly, they should be the drugs that are in a relatively late stage of clinical development or already on the market
overseas. The advanced development is already conducted overseas for these drug candidates and their efficacy and safety are
already confirmed on human subjects, thereby reducing the development risk. We utilize existing clinical data available
overseas so as to compress development timelines, reduce the development costs, and increase the likelihood of regulatory
approvals in Japan and Asian markets.
(ii) Building high-quality pipeline with exceptional search and evaluation capabilities
Our new drug search engine is connected to the diverse networks with pharmaceutical companies and bio ventures, andenables us to select promising drug candidates from the vast amount of chemical compounds after the careful review byinternal experts. Using their wealth of experience at the forefront of research and development, Scientific Advisory Board(SAB) members carefully evaluate and render final judgment on each drug candidate. The highly established screening
process up to the final selection of drug candidate, coupled with the post-POC strategy, reduces the development risk andcompresses the timelines. It also helps to understand how satisfactorily the healthcare needs are met and to improve theaccuracy of revenue projections after the product launch.
(iii) Containment of fixed costs by laboless/fabless strategy
SymBio does not own any research or production facilities, which are often regarded as the main causes for fixed costs.
Once development candidate compounds are searched and selected, we focus on value-added activities such as the formulationand implementation of development strategy and outsource other necessary routines. This enables us to reduce development
costs of pharmaceutical drugs and secure the mobility of financial strategy.
(iv) Realization of high business efficiency by “Blue Ocean” strategy
There are many cases that the standard drug used overseas cannot be prescribed in Japan or a new drug is launched in Japan
five years behind its initial approval overseas. This problem is called “drug lag” and becoming aggravated, and the term like“cancer patient refugee” has been created. The drag lug is conspicuous in our strategic therapeutic areas of oncology,
hematology, and autoimmune diseases. The market of anticancer drugs is huge and still continues to grow with the population
being aged. However, anticancer drugs have a wide range of indications and they are fragmented by type of cancer. There is
only the limited number of patients in some therapeutic areas depending on type of cancer. Extremely high degree of
specialization is required for the development of anticancer drugs in these therapeutic areas, which are often financiallyunattractive for larger pharmaceutical companies to pursue despite the high degree of development difficulty. This partiallyaccounts for the causes for drug lag. Contrarily, once a new drug succeeds in receiving an approval and reaching the market
for these therapeutic areas, we would be able achieve a superior growth and profitability due to the lack of fierce competition
by continuously expanding the indications and bringing new products into the market.
(v) Expanding Business in Asia Pacific Countries
Significant growth in medical needs and increasing demand for higher quality therapeutic options are expected in Asian
countries as they continue to undergo rapid economic development. Similar to in Japan, the trend observed is that thedevelopment of new drugs is stagnant with the population being rapidly aging in these countries. Indications in oncology,
hematology, and autoimmune diseases are emerging as areas of unmet medical needs with rising demand for effective
therapies. We secure the rights to manufacture and commercialize anticancer drugs SyB L-0501 and SyB L-1101/SyB C-1101
and a transdermal antiemetic patch SyB D-0701 in Asian countries not only in Japan.
(5) Issues to be solved by the Company- 14 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

The Company will solve the following important issues:(i) Further expansion of pipeline
In order to enhance the enterprise value as a specialty pharmaceutical company, we need to expand the pipeline throughcontinually in-licensing of new candidate drugs for development.
We have four products, SyB L-0501, SyB L-1101, SyB C-1101 and SyB D-0701 in the pipeline and clinical trials areunderway.We continue with ongoing efforts to in-license an additional pipeline.
(ii) Pursuit of life cycle management of TREAKISYM® (SyB L-0501)
In order to enhance the enterprise value, it is critical to maximize returns from each drug candidate under development byadding new indications for developed candidate drugs after their initial introduction in pursuit of life cycle management.
TREAKISYM® has received the approval for manufacture and marketing with the approved indications ofrefractory/relapsed indolent non-Hodgkin’s lymphoma and refractory/relapsed mantle cell lymphoma. For additional
indications, Phase II clinical trials were completed for refractory/relapsed aggressive non-Hodgkin's lymphoma, and Phase II
clinical trials are underway for untreated indolent non-Hodgkin's lymphoma, untreated mantle cell lymphoma andrefractory/relapsed multiple myeloma, as well as for untreated chronic lymphocytic leukemia is underway for the clinical trial.
We will add new indications in pursuit of life cycle management to maximize the value of TREAKISYM®.
(iii) Expansion to other Asian regions
SymBio positions China (including Hong Kong), South Korea, Taiwan, and Singapore as our important strategic geographic
domains in addition to Japan. In these areas, high growth in economy and medical needs is expected and we consider thatthese areas will assume increasing importance in our corporate strategy.
Among our pipelines, we plan to develop and market SyB L-0501 and SyB D-0701 in China (including Hong Kong), South
Korea, Taiwan, and Singapore as well as Japan. It is established by the result of market survey that significant medical needs
exist for SyB L-0501 and SyB D-0701 in these countries. We also plan to develop and market SyB L-1101/C-1101 in South
Korea other than Japan. We will aggressively launch clinical trials and apply for marketing approvals in these Asian countries.
(iv) Securing people
SymBio places the highest priority on people as the company management resource. We cannot make superiorachievements in exploring and developing new drugs without talent. Also, a company that considers out-licensing drugcandidates to us critically evaluates the quality of our people in due-diligence. Hence, we plan to further strengthen our humanresources by continually recruiting talent and providing development programs such as OJT and other trainings.
(v) Financial issue
There is a possibility that the Company raises funds necessary for business activities such as R&D expenditures externallyas the pipeline development progresses and the number of drug candidates increases. Therefore, we make every effort tostrengthen the financial base by continually diversifying the method for fund procurement and reducing costs through andthorough budget control.
(6) Other important matters concerning the company management(i) Third-party allotment
The Company made a resolution in December 2012 to issue unsecured convertible bond with stock acquisition rights by
way of third-party allotment and warrant in order to secure funds necessary for R&D activities.

- 15 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

4．Financial statements(1) Balance sheets
FY 2011(As of December 31, 2011)
AssetsCurrent assets
Cash and deposits
Accounts receivable-tradeMarketable securities
Merchandise and finished goods
Supplies
Prepaid expenses
Advances paid
Consumption taxes receivable
Forward exchange contracts
Other
Total current assets
Noncurrent assets
Property, plant and equipment
Buildings
Accumulated depreciation
Buildings, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
Total property, plant and equipment
Intangible assets
SoftwareLease assets
Total intangible assets
Investments and other assets
Long-term prepaid expenses
Lease and guarantee deposits
Total investments and other assets
Total noncurrent assets
Total assets- 16 -(Unit: Thousand yen)
FY 2012(As of December 31, 2012)

4,558,714
162,409
1,952,533
207,467－
79,038
124,589
69,571－
24,067
7,178,392

4,540,022
148,081300,000
164,571320
98,192
99,03639,495
21,3859,517
5,420,623

7,358(4,889)2,468
32,410(17,471)
14,93817,407

7,705(5,067)
2,637
33,921(22,837)
11,084
13,7219,541
3,189
12,7308,324
2,540
10,86424,30023,26447,56477,702
7,256,094

27,64629,33456,98081,567
5,502,190

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

FY 2011(As of December 31, 2011)(Unit: Thousand yen)
FY 2012(As of December 31, 2012)

308,953719
277,898
19,073
1,382
37,719645,746

329,768
673
195,833
15,588－56,662598,527

2,691
2,092
4,783
650,529

2,017
1,688
3,705
602,232

6,024,610

6,024,610

5,994,610
5,994,610

5,994,610
5,994,610(5,413,091)(5,413,091)(17)
6,606,110(7,146,411)(7,146,411)(17)
4,872,790

(546)

－

(546)
－
6,605,564
7,256,094－
27,167
4,899,957
5,502,190

Liabilities
Current liabilities
Accounts payable-trade
Lease obligations
Accounts payable-other
Income taxes payable
Advances received
Other
Total current liabilities
Noncurrent liabilities
Lease obligations
Provision for retirement benefits
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Legal capital surplus
Total capital surplus
Retained earnings
Other retained earnings
Retained earnings brought forward
Total retained earnings
Treasury stock
Total shareholders' equity
Valuation and translation adjustments
Valuation difference on available-for-salesecurities
Total valuation and translation adjustments
Subscription rights to shares
Total net assets
Total liabilities and net assets- 17 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(2) Statements of income

Net sales
Net sales of goods
Rights income
Total net sales
Cost of sales
Beginning goods
Cost of purchased goods
Total
Transfer to other account *3
Ending goods
Cost of goods sold
Gross profit
Selling, general and administrative expenses *1,2,3
Operating loss
Non-operating income
Interest income
Interest on securities
Insurance and dividends income
Subsidy income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Commission fee
Stock issuance cost
Foreign exchange losses
Going public expenses
Bond-issue expenses
Other
Total non-operating expenses
Ordinary loss
Extraordinary loss
Loss on retirement of noncurrent assets *4
Impact of application of accounting standard for asset
retirement obligations
Total extraordinary losses
Loss before income taxes
Income taxes-current
Total income taxes
Net loss- 18 -FY 2011(From January 1, 2011
to December 31, 2011)(Unit: Thousand yen)
FY 2012(From January 1, 2012
to December 31, 2012)

1,632,471
250,050
1,882,521

1,955,178－
1,955,178－
1,433,633
1,433,633
1,981
207,467
1,224,185
658,336
2,725,182(2,066,846)

207,467
1,321,514
1,528,982
2,211
164,571
1,362,199
592,979
2,293,253(1,700,273)

863
2,559
1,044
51,891
23
56,382

1,585
3,353
1,122
－
1,247
7,309

668
21,967
16,721
9,895
35,665－－84,919(2,095,382)

137
10,829－15,755－9,473
320
36,516(1,729,480)

－

39

5,331

－

5,331
(2,100,713)
3,800
3,800
(2,104,513)

39(1,729,520)
3,800
3,800
(1,733,320)

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(3) Statements of changes in net assets

Shareholders' equity
Capital stock
Balance at the beginning of the year
Changes of items during the year
Issuance of new shares
Total changes of items during the year
Balance at the end of the year
Capital surplus
Legal capital surplus
Balance at the beginning of the year
Changes of items during the year
Issuance of new shares
Total changes of items during the year
Balance at the end of the year
Total capital surplus
Balance at the beginning of the year
Changes of items during the year
Issuance of new shares
Total changes of items during the year
Balance at the end of the year
Retained earnings
Other retained earnings
Retained earnings brought forward
Balance at the beginning of the year
Changes of items during the year
Net loss
Total changes of items during the year
Balance at the end of the year
Total retained earnings
Balance at the beginning of the year
Changes of items during the year
Net loss
Total changes of items during the year
Balance at the end of the year
Treasury stock
Balance at the beginning of the year
Changes of items during the year
Acquisition of treasury stock
Total changes of items during the year
Balance at the end of the year

- 19 -FY 2011(From January 1, 2011
to December 31, 2011)(Unit: Thousand yen)
FY 2012(From January 1, 2012
to December 31, 2012)

3,710,830

6,024,610

2,313,780
2,313,780
6,024,610－－
6,024,610

3,680,830

5,994,610

2,313,780
2,313,780
5,994,610－－
5,994,610

3,680,830

5,994,610

2,313,780
2,313,780
5,994,610－－
5,994,610(3,308,577)(5,413,091)(2,104,513)(2,104,513)(5,413,091)(1,733,320)(1,733,320)(7,146,411)(3,308,577)(5,413,091)(2,104,513)(2,104,513)(5,413,091)(1,733,320)(1,733,320)(7,146,411)

－

(17)

(17)
(17)
(17)

－
－
(17)

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

FY 2011(From January 1, 2011
to December 31, 2011)
Total shareholders' equity
Balance at the beginning of the year
Changes of items during the year
Issuance of new shares
Net loss
Acquisition of treasury stock
Total changes of items during the year
Balance at the end of the year
Valuation and translation adjustments
Valuation difference on available-for-sale securities
Balance at the beginning of the year
Changes of items during the year
Net changes of items other than shareholders'equityTotal changes of items during the year
Balance at the end of the year
Total valuation and translation adjustments
Balance at the beginning of the year
Changes of items during the year
Net changes of items other than shareholders'equityTotal changes of items during the year
Balance at the end of the year
Subscription rights to shares
Balance at the beginning of the year
Changes of items during the year
Net changes of items other than shareholders'equityTotal changes of items during the year
Balance at the end of the year
Total net assets
Balance at the beginning of the year
Changes of items during the year
Issuance of new shares
Net loss
Acquisition of treasury stock
Net changes of items other than shareholders'equityTotal changes of items during the year
Balance at the end of the year

- 20 -(Unit: Thousand yen)
FY 2012(From January 1, 2012
to December 31, 2012)

4,083,082

6,606,110

4,627,560(2,104,513)(17)
2,523,028
6,606,110－(1,733,320)－(1,733,320)
4,872,790

(18)

(546)

(527)

546

(527)
(546)

546
－

(18)

(546)

(527)

546

(527)
(546)

546
－

－

－

－

27,167－－

27,167
27,167

4,083,064

6,605,564

4,627,560(2,104,513)(17)－(1,733,320)
－

(527)

27,7132,522,500
6,605,564(1,705,606)
4,899,957

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(4) Statements of cash flows

Net cash provided by (used in) operating activities
Loss before income taxes
Depreciation
Amortization of guarantee deposits
Impact of application of accounting standard for asset
retirement obligations
Share-based compensation expenses
Increase (decrease) in provision for retirement benefits
Interest income
Interest expenses
Foreign exchange losses (gains)
Stock issuance cost
Commission fee
Loss on retirement of noncurrent assets
Decrease (increase) in accounts receivable-trade
Decrease (increase) in inventories
Decrease (increase ) in prepaid expenses
Decrease (increase) in advances paid
Decrease (increase) in consumption taxes receivable
Decrease (increase) in other current assets
Decrease (increase) in long-term prepaid expenses
Increase (decrease) in accounts payable-trade
Increase (decrease) in accounts payable-other
Increase (decrease) in accrued consumption taxes
Increase (decrease) in advances received
Increase (decrease) in other current liabilities
Other
SubtotalInterest and dividends income received
Commitment fees paid
Interest expenses paid
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Decrease (increase) in time deposits
Purchase of marketable securities
Proceeds from redemption of securities
Purchase of property, plant and equipment
Purchase of intangible assets
Payments for lease and guarantee deposits
Proceeds from collection of lease and guarantee
deposits
Net cash provided by (used in) investing activities- 21 -FY 2011(From January 1, 2011
to December 31, 2011)(Unit: Thousand yen)
FY 2012(From January 1, 2012
to December 31, 2012)(2,100,713)
8,167
2,398

(1,729,520)
8,560
1,444

5,331

－

－
257
(3,422)668
23,647
16,721
21,967－(156,474)(207,467)
11,728(38,507)(69,571)(20,592)(24,300)
307,784
153,739(8,107)－
13,889404(2,062,451)
3,688(10,829)(664)(3,800)(2,074,057)

27,167(404)(4,938)137
1,630－
10,82939
14,32842,895(19,183)
25,55230,076(7,156)(3,346)
20,814(82,105)－(1,382)
15,458291(1,648,808)
4,917(10,800)(96)(3,800)(1,658,588)－(201,283)
100,000(1,422)(10,940)(4,257)(300,000)(300,000)
200,000(1,858)(1,190)(8,105)546

590(117,356)(410,563)

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

FY 2011(From January 1, 2011
to December 31, 2011)(Unit: Thousand yen)
FY 2012(From January 1, 2012
to December 31, 2012)－
4,627,560(16,721)(17)
4,610,820

(719)
－
－
－
(719)

(24,193)(1,084)

2,395,213
3,915,765
6,310,978(2,070,956)
6,310,9784,240,022

Net cash provided by (used in) financing activities
Repayments for lease obligations
Proceeds from issuance of common stock
Payments for issuance of common stock
Payments for acquisition of treasury stock
Net cash provided by (used in) financing activities
Effect of foreign exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period*(5) Events and conditions with indicate there could be substantial doubt about going concern assumption
None to be reported.

(6) Significant Accounting Policies
1.

Valuation basis and method of marketable and investment securities
Available-for-sale securities with determinable market value
Available-for-sale securities with a determinable market value are stated at fair value with any changes in
unrealized holding gain or loss, net of applicable income taxes, included directly in shareholders’ equity.
Cost of securities sold is calculated by the moving average method.
Available-for-sale securities without determinable market value
Available-for-sale securities without determinable market value are stated at cost determined by themoving average method.

2.

Valuation basis and method of derivative transactions
Derivative financial instruments are stated at fair value.

3.

Valuation basis and method of inventories
Inventories held for the purpose of ordinary sale are measured at lower of cost determined by the weightedaverage method or net selling value.

4.

Depreciation of property, plant and equipment(1) Property, plant and equipment (excluding lease assets)
Depreciation of property, plant and equipment is computed by the straight-line method.
The useful lives of major property, plant and equipment are summarized as follows:
Buildings
2 to 18 years
Tools, furniture and fixtures
4 to 10 years(2) Intangible assets (excluding lease assets)
Amortization of intangible assets is computed by the straight-line method.
Capitalized software costs are being amortized over the period of the internal use of 5 years.
(3) Lease assets
Depreciation of lease assets is computed by the straight-line method over the lease term with no residual
value.

5.

Deferred assets(1) Stock issuance costs are charged to income as incurred.
- 22 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(2) Bond-issue expenses are charged to income as incurred.

6.

Foreign currency translation
Monetary assets and liabilities denominated in foreign currencies are translated into yen at the spot exchange
rates prevailing at the balance sheet dates, and resulting gains or losses are credited or charged to income.

7.

Basis for reserves and provisions(1) Allowance for doubtful accounts
The allowance for doubtful accounts is provided at an amount determined based on the historical experienceof bad debt with respect to ordinary receivables and an estimate of uncollectible amounts determined byreference to specific doubtful receivables from customers which are experiencing financial difficulties.
For FY 2011 and FY 2012, no allowance for doubtful accounts is provided due to no historical experience ofbad debt and no receivable balances that are deemed uncollectible.
(2) Provision for retirement benefits
The provision for retirement benefits is provided at an amount to be required as of the balance sheet date.

8.

Cash and cash equivalents in the statements of cash flows
Cash and cash equivalents consist of cash on hand, cash in banks which can be withdrawn at any time andshort-term investments with a maturity of three months or less that can easily be converted to cash and are
subject to little risk of change in value.

9.

Other significant basis for the preparation of financial statements
Accounting for consumption tax
Transactions are recorded at amounts exclusive of consumption tax.

(7) Changes in presentation“Insurance and dividends income” included in “Other” under non-operating income for FY 2011 is shown as aseparate line item for FY 2012 since the amount exceeded 10% of total non-operating income. The amount of“Dividends income of insurance” for FY 2011 was 1,044 thousand yen.

(8) Notes to financial statements(Balance sheets)
1. The Company has overdraft and commitment line contracts with three banks in a business relationship to efficiently
procure working capital. The status of the bank overdraft and loan commitments based on these contracts at the end ofeach fiscal year is as follows:(Unit: Thousand yen)
FY 2011(As of December 31, 2011)
Total amounts of bank overdraft limit andloan commitment line
Balance of borrowing outstanding
Unused balance

FY 2012(As of December 31, 2012)

1,350,000

1,350,000－
1,350,000－
1,350,000(Statements of income)* 1 Selling expense ratio is roughly 1.4% and 2.1% for FY 2011 and FY 2012, respectively, and administrative
expense ratio is roughly 98.6% and 97.9% for FY 2011 and FY 2012, respectively.
Major expense items and amounts are as follows.

- 23 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Unit: Thousand yen)
FY 2011(From January 1, 2011
to December 31, 2011)

FY 2012(From January 1, 2012
to December 31, 2012)

98,271
265,620713
1,945,029
7,653

106,108
305,679921
1,438,125
6,990

Directors’ compensation
Salaries
Retirement benefit expenses
Research and development expenses
Depreciation expenses*2*3

Total amounts of research and development expenses included in general and administrative expenses(Unit: Thousand yen)
FY 2011(From January 1, 2011
to December 31, 2011)

FY 2012(From January 1, 2012
to December 31, 2012)

1,945,029

1,438,125

Details of transfer to other accounts are as follows.
(Unit: Thousand yen)
FY 2011(From January 1, 2011
to December 31, 2011)

FY 2012(From January 1, 2012
to December 31, 2012)

Selling, general and administrative
expenses*4

Selling, general and administrative
expenses

1,981

2,211

Details of loss on retirement of noncurrent assets are as follows.
(Unit: Thousand yen)
FY 2011(From January 1, 2011
to December 31, 2011)

FY 2012(From January 1, 2012
to December 31, 2012)－

Software

Software39(Statements of changes in net assets)
FY 2011 (From January 1, 2011 to December 31, 2011)
1. Shares issued and outstanding / Treasury stock(Unit: Number of shares)
At the beginning of
the fiscal year

IncreaseAt the end of the
fiscal year

Decrease

Shares issued
Common stock (Note 1)
Total

111,737

19,019,163－

19,130,900

111,737

19,019,163－

19,130,900

－

75

－

75

－

75

－

75

Treasury stock
Common stock (Note 2)
Total(Note) 1. Increase in number of shares outstanding of common stock by 19,019,163 shares is due to an increase of
28,572 shares by new stock issuance by third-party allotment, an increase of 5,100,000 shares by new stock
issuance by offering and an increase of 13,890,591 shares by 100-for-1 stock split on June 2, 2011.
2. Increase in number of treasury stock of common stock of 75 shares is due to the purchase of fractional shares.
2. Stock acquisition rights and treasury acquisition rights- 24 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

Type ofshares to beissuedDescription

Company

Number of shares to be issued
At thebeginning of Increase
the fiscal year

The
Stock acquisition rights
Company as stock options

Balance as ofDecember 31,
2011(Thousand
yen)

―

Total

At the end
Decrease of the fiscal
year

－

－

－

－

－

－

－

－

－

－

(Note) The information about type of shares to be issued and the number of shares to be issued is described in “Stock
options”.
3. Dividends
None to be reported.
FY 2012 (From January 1, 2012 to December 31, 2012)
1. Shares issued and outstanding / Treasury stock(Unit: Number of shares)
At the beginning of
the fiscal year

IncreaseAt the end of the
fiscal year

Decrease

Shares issued
Common stockTotal

19,130,900－－

19,130,900

19,130,900－－

19,130,900

75

－

－

75

75

－

－

75

Number of shares to be issued

Balance
as ofDecember31, 2012(Thousandyen)

Treasury stock
Common stock
Total

2. Stock acquisition rights and treasury acquisition rights

Company

Description

The
Stock acquisition rights
Company as stock options
Total

Type ofshares to beissued―At thebeginning of
the fiscal
year

Increase

DecreaseAt the end of
the fiscal
year

－

－

－

－

27,167－－－－

27,167(Note) The information about type of shares to be issued and the number of shares to be issued is described in “Stock
options”.
3. Dividends
None to be reported.
(Statements of cash flows)* Cash and cash equivalents as of the fiscal year end are reconciled to the accounts reported in the balance
sheets as follows:- 25 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Unit: Thousand yen)
FY 2011(From January 1, 2011
to December 31, 2011)
Cash and deposits
Marketable securities
Time deposits with maturities of more than three months
Debt securities with a remaining maturity in excess of
three month
Cash and cash equivalents

FY 2012(From January 1, 2012
to December 31, 2012)

4,558,714
1,952,533－

4,540,022
300,000(300,000)(200,270)(300,000)

6,310,9784,240,022(Lease transactions)
Finance lease transaction
Finance lease transactions other than those which transfer the ownership of leased property(a) Description of lease assets
Intangible assets ---Software(b) Depreciation and amortization of lease assets
Depreciation and amortization of lease assets is described in significant accounting policies “4.
Depreciation of property, plant and equipment.”(Financial instruments)
1. Financial instruments(1) Policies for financial instruments
The Company procures the funds necessary in light of the pipeline development plan (primarily by thirdparty allotment and offering by new stock issuance). Temporary surplus fund is invested in financial
instruments which are highly safe and liquid.
As a principle, the Company does not enter into derivative transactions for speculative trading purpose
but uses them within the scope prescribed in the internal rules.
(2)Types of financial instruments and related risks
Operating receivables such as accounts receivable-trade and advances paid in connection with joint
development are exposed to credit risk of customers and joint development partners. Operating receivables
denominated in foreign currencies are exposed to foreign exchange fluctuation risk.
The Company intends to invest in marketable and investment securities which have relatively low risk offalling below initial investments. However, it might carry a finite risk.
Operating payables such as accounts payable-trade and accounts payable-other are mostly due within
two months. Operating payables denominated in foreign currencies are exposed to foreign exchange
fluctuation risk.
The Company uses derivative transactions to avoid foreign exchange fluctuation risks and enters into
forward exchange contracts within the scope prescribed in the internal rules based on balances ofreceivables and payables denominated in foreign currencies as well as actual volume of exports andimports transactions denominated in foreign currencies.
Lease and guarantee deposits are mostly security deposits related to rented office premises and theirrefunds are subject to the credit risk of the lessor.
Lease obligations are associated with the finance lease transactions that intend to finance capital
expenditures and the longest maturity of lease term is 4 years after December 31, 2012.
(3)Risk management for financial instruments(a) Monitoring of credit risks (the risk that customers or counterparties may default)
In accordance with the internal credit policies for managing credit risk arising from operatingreceivables, the Company’s marketing department periodically monitors the credit worthiness of major
customers and monitors due dates and outstanding balances by individual customer. In addition, the- 26 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

Company is making efforts to promptly identify and mitigate risks of bad debts from customers who arehaving financial difficulties.
The Company enters into derivative transactions only with financial institutions which have a soundcredit profile in order to mitigate the counterparty risk.
(b) Monitoring of market risk (the risk arising from fluctuations in foreign exchange rates, interest rates
and others)
The Company deposits cash primarily with financial institutions with high credit ratings.
For marketable and investment securities, the Company intends to avoid risks of falling below initialinvestments by investing in securities with the satisfactory credit rating and investment period in
accordance with the internal investment policies.
The Company enters into forward exchange contracts in order to avoid foreign exchange fluctuation
risks in connection with receivables and payables denominated in foreign currencies.
Followed by appropriate authorization procedures prescribed in the internal rules, Finance andaccounting department executes and monitors derivative transactions. Monthly transaction performaces
are reported to the executive management committee.
(c) Monitoring of liquidity risks (the risk that the Company may not be able to meet its obligations onscheduled due date)
Based on the report from each department, the responsible department of the Company prepares andupdates its cash flow plans on a timely basis and ensures to maintain liquidity on hand to manage
liquidity risk.
(4)Supplementary explanation of the estimated fair value of financial instruments
The fair value of financial instruments is based on their quoted market price, if available. When there isno quoted market price available, fair value is reasonably estimated. Since various assumptions andfactors are reflected in estimating the fair value, different assumptions and factors could result indifferent fair value. In addition, the notional amounts of derivatives in notes to “Derivative transactions”
are not necessarily indicative of the actual market risk involved in derivative transactions.
(5)Concentration of credit risk
As of December 31, 2012, all operating receivables are from one particular major customer.
2. Fair value of financial instruments
Carrying value on the balance sheets, fair values and their differences are as follows. The financial instruments whose
fair value is extremely difficult to determine are not included. (See (Note) 2.)- 27 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

FY 2011 (As of December 31, 2011)(Unit: Thousand yen)
Carrying value

Fair value

Differences

4,558,714

4,558,714－

162,409

162,409－

1,952,533

1,952,533－(4) Advances paid

124,589

124,589－(5) Consumption taxes receivable

69,571

69,571－

6,867,818

6,867,818－

308,953

308,953

－

719

719

－

(3) Accounts payable-other277,898

277,898－(4) Income taxes payable

19,073

19,073－(5) Lease obligations (non-current)

2,691

2,691

－

609,336609,336

－

－

－

－

(1) Cash and deposits(2) Accounts receivable-trade(3) Marketable securities

Assets, total(1) Accounts payable-trade(2) Lease obligations (current)

Liabilities, total
Derivative transactions, total

FY 2012 (As of December 31, 2012)(Unit: Thousand yen)
Carrying value

Fair value

Differences

4,540,022

4,540,022－(2) Accounts receivable-trade148,081

148,081－(3) Marketable securities

300,000

300,000－(4) Advances paid

99,03699,036－(5) Consumption taxes receivable

39,49539,495－

5,126,635

5,126,635－

329,768

329,768

－

673

673

－

(3) Accounts payable-other

195,833

195,833－(4) Income taxes payable

15,58815,588－(5) Lease obligations (non-current)

2,017

2,017

－

Liabilities, total

543,882

543,882－

Derivative transactions, total (*1)

21,385

21,385－(1) Cash and deposits

Assets, total(1) Accounts payable-trade(2) Lease obligations (current)(* 1) Net assets and liabilities arising from derivative transactions are presented on a net basis.
(Note) 1. Fair value measurement of financial instruments and other matters related to securities and derivativetransactions
Assets- 28 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(1) Cash and deposits, (2) Accounts receivable-trade, (4) Advances paid and (5) Consumption taxes receivable
The carrying value is deemed as the fair value since these are scheduled to be settled in a short period oftime.
(3) Marketable securities
The fair value of debt securities is based on the quoted price obtained from financial institutions. See notes
to “Marketable and investment securities” for notes pertaining to securities by holding purpose.
Liabilities(1) Accounts payable-trade, (3) Accounts payable-other and (4) Income taxes payable
The carrying value is deemed as the fair value since these are scheduled to be settled in a short period oftime.
(2) Lease obligations (current) and (5) Lease obligations (non-current)
The fair value of lease obligations, that is determined at present value calculated by discounting total amounts
of principle and interests at a presumable rate used for similar new lease transactions.
Derivative transactions
See notes to “Derivative transactions”
2. Financial instruments whose fair value is extremely difficult to determine.
(Unit: Thousand yen)
FY 2011(As of December 31, 2011)
Lease and guarantee deposits

FY 2012(As of December 31, 2012)

23,26429,334

Lease and guarantee deposits are not included in above tables since no market quote is available and their fairvalue is extremely difficult to determine.
3. The redemption schedule for monetary assets and securities with maturities
FY 2011 (As of December 31, 2011)(Unit: Thousand yen)
Due after one
Due after fiveDue in one year
Due after ten
year through five years through ten
or less
years
years
years
4,558,543－－－

Deposits

162,409－－－200,000－－－(2) Other

1,752,263－－－

Advances paid

124,589－－－

6,797,805－－－

Accounts receivable-trade
Securities
Available-for-securities with maturities(1) Debt securities

Total- 29 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

FY 2012 (As of December 31, 2012)(Unit: Thousand yen)
Due after one
Due after fiveDue in one year
Due after ten
year through five years through ten
or less
years
years
years
4,539,915－－－

Deposits

148,081－－－

Others300,000－－－

Advances paid

99,036－－－

5,087,032－－－

Accounts receivable-trade
Securities
Available-for-securities with maturities

Total

4. Maturities of lease obligations after the fiscal year end
FY 2011 (As of December 31, 2011)

Due in one
year or lessLease obligations(current)
Lease obligations(non-current portion)
Total

Due after one
year throughtwo years(Unit: Thousand yen)
Due after two Due after three Due after four
Due after five
years through years through years throughyears
three years
four years
five years

719

－

－

－

－

－

－

673

682

692

642

－

719

673

682

692

642

－

FY 2012 (As of December 31, 2012)

Due in one
year or lessLease obligations(current)
Lease obligations(non-current)
Total

Due after one
year throughtwo years(Unit: Thousand yen)
Due after two Due after three Due after four
Due after five
years through years through years throughyears
three years
four years
five years

673

－

－

－

－

－

－

682

692

642

－

－

673

682

692

642

－

－

- 30 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Marketable and investment securities)
1. Available-for-sale securities
FY 2011 (As of December 31, 2011)(Unit: Thousand yen)Type

Carrying value

Acquisition cost

Difference

－

－

－

(a) Government
and municipal
bond

－

－

－

(b) Corporate bond

200,270

200,816

(546)

－

－

－

1,752,263

1,752,263－

1,952,533

1,953,079(546)(1)Equity securities(2)Debt securities
Carrying value does notexceed the acquisition
cost(c) Other(3)OtherTotal

FY 2012 (As of December 31, 2012)(Unit: Thousand yen)Type

Carrying value

Acquisition cost

Difference

－

－

－

(a) Government
and municipal
bond

－

－

－

(b) Corporate bond

－

－

－

300,000

300,000

－

－

－

－

300,000

300,000－(1)Equity securities(2)Debt securities
Carrying value does notexceed the acquisition
cost(c) Other(3)OtherTotal- 31 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

2. Available-for-sale securities soldFY 2011 (From January 1, 2011 to December 31, 2011)
None to be reported.
FY 2012 (From January 1, 2012 to December 31, 2012)(Unit: Thousand yen)Type

Proceeds

Realized gains

Realized losses

－

－

－

(a) Government andmunicipal bond

－

－

－

(b) Corporate bond

－

－

－

(c) Other－－－

1,853,428－－

1,853,428－－(1)Equity securities(2)Debt securities(3)Other
Total(Derivative transactions)
1. Derivative transactions to which hedge accounting is not applied
Currency-related transaction
FY 2011 (As of December 31, 2011)
None to be reported.
FY 2012 (As of December 31, 2012)(Unit: Thousand yen)Classification

Type

Portion due
Notional amount after one year
included herein

Fair value

Difference

Forward exchange
contract
OTC transactions

Buy
Euro
Total

(Note)

242,027－

21,385(21,385)

242,027－

21,385(21,385)

Fair value measurement
The fair value is measured based on the quoted prices obtained from financial institutions with business
relationship.
2. Derivative transactions to which hedge accounting is applied
None to be reported.

- 32 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Retirement benefits)
1. Outline of retirement benefit plans
The Company has adopted a lump-sum payment plan as a defined benefit plan and a defined contribution pension plan
as a defined contribution plan.
2. Retirement benefit obligation
FY 2011(As of December 31,
2011)(Unit: Thousand yen)
FY 2012(As of December 31,
2012)(1) Retirement benefit obligation(2,092)(1,688)(2) Provision for retirement benefits(2,092)(1,688)(Note)The simplified method is applied to calculate amounts of retirement benefit obligation. That is, the amounts
shown as retirement benefit obligation are the payments required for voluntary retirement as of each fiscal
year end.

3. Retirement benefit expenses(Unit: Thousand yen)
FY 2011(From January 1, 2011
to December 31, 2011)

FY 2012(From January 1, 2012
to December 31, 2012)

1,750

2,133

395

311

1,355

1,822

Retirement benefit expenses(1) Service costs(2) Contribution made for defined contribution
pension plan

4. Assumption used in accounting for retirement benefit obligation
Actuarial assumption is omitted since the Company applies the simplified method.
(Stock options)
1. The account name and the amount of stock options charged as expenses(Unit: Thousand yen)
FY 2011(From January 1, 2011
to December 31, 2011)
Selling, general andadministrative expenses

FY 2012(From January 1, 2012
to December 31, 2012)－- 33 -

27,167

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

2. Description of stock options/ Changes in the size of stock options(1) Description of stock options
The 1st Series
Directors of the Company
3
Auditor & supervisory board member of
Individuals covered by thethe Company
1plan and number of persons
Employees of the Company
6
grantedExternal collaborators
12
Total
22
Class and number of shares
to be issued upon the
Common stock 390,000 shares
exercise of the stock option
Grant dateJune 20, 2005
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires due
Vesting condition
to the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period
Vesting period is not fixed.
Exercise period
From June 21, 2007 to June 20, 2015

The 5th Series
Directors of the Company
1
Individuals covered by the
Employees of the Company 16plan and number of persons
External collaborators
1
grantedTotal
18
Class and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Common stock

117,000 shares

January 31, 2006
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From February 1, 2008 to September 1,
2015- 34 -The 2nd Series

External collaborator

1

Common stock 2,000 shares
June 22, 2005

Same as on the left

Same as on the left
From June 23, 2007 to June 22, 2015

The 6th Series
Auditors & supervisory board members of
the Company
1
Employees of the Company
3
External collaborators
6
Total
10
Common stock

45,000 shares

April 18, 2006

Same as on the left

Same as on the left
From April 19, 2008 to March 30, 2016

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

The 7th Series
Directors of the Company
6
Auditors & supervisory board members of
the Company
2
Employees of the Company
16
External collaborators
9
Total
33
Common stock

200,000 shares

The 8th Series
Employees of the Company
External collaborators
Total

Common stock

6
5
11

52,000 shares

July 1, 2006
December 4, 2006
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or theSame as on the left
compulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
Same as on the left
From July 2, 2008 to March 30, 2016
From December 2, 2008 to March 30, 2016

The 9th Series
The 11th Series
Directors of the Company
3
Individuals covered by the
Employees of the Company
6
Auditors & supervisory board members ofplan and number of persons
External collaborators
3
the Company
2
granted
Total
9
Total
5
Class and number of shares
to be issued upon the
Common stock 66,000 shares
Common stock 34,000 shares
exercise of the stock option
Grant dateFebruary 1, 2007
March 15, 2007
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires due
Vesting condition
to the expiry of her/his term or theSame as on the left
compulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period
Vesting period is not fixed.
Same as on the left
From January 24, 2009 to January 23,
From March 3, 2009 to March 2, 2017
Exercise period2017- 35 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

The 12th Series
The 13th Series
Directors of the Company
5
Individuals covered by the
Employees of the Company
33
Auditor & supervisory board member ofplan and number of persons
External collaborators
12
the Company
1
granted
Total
45
Total
6
Class and number of shares
to be issued upon the
Common stock 82,000 shares
Common stock 170,000 shares
exercise of the stock option
Grant dateAugust 29, 2007
August 29, 2007
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires due
Vesting condition
to the expiry of her/his term or theSame as on the left
compulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period
Vesting period is not fixed.
Same as on the left
Exercise period
From August 29, 2009 to August 28, 2017 From August 29, 2009 to August 28, 2017

- 36 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

The 14th Series
The 16th Series
Directors of the Company
5
Individuals covered by the
Auditor & supervisory board member ofplan and number of persons
External collaborators
14
the Company
1
grantedTotal
6
Class and number of shares
to be issued upon the
Common stock 207,000 shares
Common stock 85,000 shares
exercise of the stock option
Grant date
October 1, 2008
October 1, 2008
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires due
Vesting condition
to the expiry of her/his term or theSame as on the left
compulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period
Vesting period is not fixed.
Same as on the left
From October 1, 2010 to September 30,
From October 1, 2010 to September 30,
Exercise period
2018
2018

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

The 17th Series
Directors of the Company
3
Auditor & supervisory board member of
the Company
1
Total
4
Common stock

72,000 shares

March 18, 2009
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From March 19, 2011 to March 18, 2019- 37 -

The 19th Series
External collaborators

Common stock2

12,500 shares

March 18, 2009Same as on the left

Same as on the left
From March 19, 2011 to March 18, 2019

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

The 20th Series
Directors of the Company
6
Auditor & supervisory board member of
the Company
1
Total
7
Common stock

361,000 shares

March 31, 2010
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From April 1, 2012 to March 31, 2020

- 38 -The 21st Series
Employees of the Company

Common stock50

326,500 shares

March 31, 2010Same as on the left

Same as on the left
From April 1, 2012 to March 31, 2020

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

The 22nd Series
Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

External collaborators

Common stock

The 23rd Series
13

Employees of the Company

153,000 shares

Common stock

March 31, 2010
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From April 1, 2012 to March 31, 2020

The 24th Series
Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Directors of the Company

Common stock

32,000 shares

October 15, 2010Same as on the left

Same as on the left
From October 15, 2012 to October 14,
2020
The 25th Series

5

192,000 shares

March 31, 2011
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From March 31, 2013 to March 30, 2021

- 39 -

9

Employees of the Company

Common stock59

195,000 shares

March 31, 2011

Same as on the left

Same as on the left
From March 31, 2013 to March 30, 2021

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

The 26th Series
Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Directors of the Company

Common stock

The 27th Series
4

Employees of the Company

362,500 shares

Common stock

May 2, 201270

430,700 shares

May 2, 2012

No specific conditions are prescribed in theallotment agreement of stock acquisition rights
entered between the Company and the person
granted, except for certain vesting conditions
stipulated in the exercise condition. The
exercise conditions are described in *(1) to (6).
The period that fulfills the requirement of theexercise condition* (2) and (3).

From April 18, 2014 to April 17, 2022

Same as on the left

Same as on the left
From April 18, 2014 to April 17, 2022

The 28th Series
Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Employees of the Company

Common stock

5

16,500 shares

September 28, 2012
No specific conditions are prescribed in theallotment agreement of stock acquisition rights
entered between the Company and the person
granted, except for certain vesting conditions
stipulated in the exercise condition. The
exercise conditions are described in *(1) to (6).
The period that fulfills the requirement of theexercise condition *(2) and (3).

From September 14, 2014 to September
13, 2022※ (1) Fraction less than one unit of a stock acquisition right shall be un-exercisable.
(2) Those who were granted the right may exercise all or part of the rights in accordance with the following classifications:＜The 26th Series and the 27th Series stock option＞(a) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-fourth (1/4) from
April 18, 2014 to April 17, 2015.
(b) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-half (1/2) from April
18, 2015 to April 17, 2016.
(c) Those who were granted the stock acquisition rights may exercise the rights within the limit of three-fourths (3/4) from
April 18, 2016 to April 17, 2017(d) Those who were granted the stock acquisition rights may exercise all the rights from April 18, 2017 to April 17, 2022
＜The 28th Series stock option＞(a) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-fourth (1/4) from
September,14, 2014 to September 13, 2015.
(b) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-half (1/2) from
September 14, 2015 to September 13, 2016

- 40 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(c) Those who were granted the stock acquisition rights may exercise the rights within the limit of three-fourths (3/4) from
September 14, 2016 to September 13, 2017(d) Those who were granted the stock acquisition rights may exercise all the rights from September 14, 2017 to September
13, 2022(3) Those who received the allotment of the stock acquisition rights (hereinafter the "“Person Granted”) must be in a status of thedirector, auditor & supervisory board member or employee of the Company or its affiliates at the time of exercise. However,this is not necessarily the cases where;(a) The Person Granted is the director or auditor & supervisory board membe of the Company or its affiliates and retires dueto the expiry of her/his term.
(b) The Person Granted is the employee of the Company or its affiliates and retires due to the compulsory retirement.
(c) The Person Granted is the director, auditor & supervisory board member or employee of the Company or its affiliates andthe board of directors resolves that he/she resigns or retires with honorable recognition.
(4) The Person Granted shall exercise the rights starting from the date of resolution by the below-mentioned stockholders’ meetingor the board of directors’ meeting until one day before the effective date of the Organizational Restructuring as followed,
regardless the conditions of exercise period originally stipulated, when the Organizational Restructuring are approved by the
resolution of the Company’s stockholders’ meeting (including the case where resolution of a stockholders’ meeting is deemed
to exist pursuant to the provision of Article 319 of the Companies Act) or the board of directors’ meeting (limited to the casewhere no stockholders’ meeting is required for the said Organizational Restructuring) before the exercise period (hereinafter“Exercise Period”) of the stock acquisition rights comes into effect: an absorption-type merger or an incorporation-typemerger where the Company becomes a dissolving company and an absorption-type split or an incorporation-type company
split where the Company becomes a split company or a share exchange or a share transfer where the Company becomes awholly-owned subsidiary (collectively, “Organizational Restructuring” as mentioned above).
(5) In the event where;(a) The Person Granted died before the exercise period comes into effect, the inheritor shall exercise the rights of up to one-half(1/2) within six months from the date of inherited, or(b) The Person Granted died during the exercise period, the inheritor shall exercise all the rights within six months from the dateof inherited.
However, in the event that the inheritor died, the rights shall be discarded and shall not be exercised by his/her inheritor.
(6) The stock acquisition rights shall not be offered for pledge or disposed of in any other way.

- 41 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(2) Change in the size of stock options
The number of stock option is convereted into the number of shares subjest to the numbers exist in FY2012(a) Number of stock options(Unit: Number of shares)stndth
The 1 Series
The 2 Series
The 4 Series
The 5th Series
Grant dateJune 20, 2005
June 22, 2005
December 1, 2005 January 31, 2006
Non-vested shares:
At the beginning of the year－－－－
Granted－－－－Expired－－－－
Vested－－－－At the end of the year－－－－
Vested shares:
At the beginning of the year
361,000
2,000
5,000
84,500
Vested－－－－Exercised－－－－
Expired
10,000－5,000
82,500At the end of the year
351,000
2,000
－
2,000

th

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

The 6 Series
April 18, 2006

(Unit: Number of shares)
The 8 Series
The 9th Series
December 4, 2006 February 1, 2007thth

The 7 Series
July 1, 2006

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

13,000－－11,0002,000

156,000－－
95,00061,00019,000－－18,0001,000

54,000－－51,0003,000

The 10th Series
February 1, 2007

The 11th Series
March 15, 2007

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

24,000－－24,000－25,000－－18,0007,000

73,000－－50,00023,000121,000－－
60,00061,000- 42 -(Unit: Number of shares)
The 12th Series
The 13th Series
August 29, 2007
August 29, 2007

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

(Unit: Number of shares)
The 16th Series
The 17th Series
October 1, 2008
March 18, 2009

The 14th Series
October 1, 2008

The 15th Series
October 1, 2008

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

187,000－－
159,000
28,000139,000－－
139,000－

85,000－－15,00070,00071,000－－67,0004,000(Unit: Number of shares)
The 20th Series
The 21st Series
March 31, 2010
March 31, 2010

The 18th Series
March 18, 2009

The 19th Series
March 18, 2009

－
－
－
－
－

－
－
－
－
－

361,000－－
361,000－

276,500－－
276,500－

80,000－－80,000－12,500－－10,0002,500－
361,000－－
361,000－
276,500－
17,000259,500- 43 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

The 23rd Series
October 15, 2010

153,000－－
153,000－

32,000－－32,000－

192,000－－－
192,000

192,000－
7,000－
185,000－
153,000－－
153,000－
32,000－－32,000

－
－
－
－
－

－
－
－
－
－

th

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

(Unit: Number of shares)
The 24th Series
The 25th Series
March 31, 2011
March 31, 2011

The 22nd Series
March 31, 2010

The 26 Series
May 2, 2012

(Unit: Number of shares)
The 27 Series
The 28th Series
May 2, 2012
September 28, 2012
th－362,500－－
362,500－
430,700
29,300－401,400－
16,500－－16,500

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

- 44 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(b) Per share prices
Grant date
Exercise price (yen)Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen)Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen)Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen)Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen)Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen)Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

The 1st Series
June 20, 2005
500

The 2nd Series
June 22, 2005
500

The 5th Series
January 31, 2006
1,000

The 6th Series
April 18, 2006
1,000

－

－

－

－

－

－

－

－

The 7th Series
July 1, 2006
1,500

The 8th Series
December 4, 2006
1,500

The 9th Series
February 1, 2007
1,500

The 11th Series
March 15, 2007
1,500

－

－

－

－

0

0

0

0

The 12th Series
August 29, 2007
1,500

The 13th Series
August 29, 2007
1,500

The 14th Series
October 1, 2008
1,200

The 16th Series
October 1, 2008
1,200

－

－

－

－

0

0

0

0

The 17th Series
March 18, 2009
1,200

The 19th Series
March 18, 2009
1,200

The 20th Series
March 31, 2010
600

The 21st Series
March 31, 2010
600

－

－

－

－

0

0

0

0

The 22nd Series
March 31, 2010
600

The 23rd Series
October 15, 2010
600

The 24th Series
March 31, 2011
700

The 25th Series
March 31, 2011
700

－

－

－

－

0

0

0

0

The 26th Series
May 2, 2012570

The 27th Series
May 2, 2012570

The 28th Series
September 28, 2012
570

－

－

－

(a) 179(a) 179(a) 203(b) 187(c) 195(b) 187(c) 195(b) 208(c) 213(d) 202(d) 202(d) 217Note）Each of (a), (b), (c) and (d) above is corresponding to (a), (b), (c) and (d) of exercise period in the table shown on 2 (1).

- 45 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

3. Method for estimating the fair value of stock options
The method for estimating the fair value of stock options that were granted in the 26th, 27th and 28th Series during thisfiscal year is estimated based on the following method.
The 26th Series
The 27th Series
The 28th Series
Black-Scholes(a) Estimate technique used
option pricing
Same as on the left Same as on the leftmodel(b) Major assumptions andestimate method
Volatility of stock price73.066%73.066%127.923%(Note 2)Estimated remaining(a) 5.96 years(a) 5.96 years(a) 5.96 years
outstanding period(b) 6.46 years(b) 6.46 years(b) 6.46 years(Note 3)(c) 6.96 years(c) 6.96 years(c) 6.96 years(d) 7.46 years

Estimated dividend(Note 4)
Risk free interest rate
(Note 5)(d) 7.46 years

0 yen per share

0 yen per share(d) 7.46 years
0 yen per share(a) 0.370％(b) 0.440％(a) 0.370％(b) 0.440％(a) 0.288％(b) 0.344％(c) 0.494％(d) 0.550％(c) 0.494％(d) 0.550％(c) 0.401％(d) 0.464％

Note: 1. Each of (a), (b), (c) and (d) above is corresponding to (a), (b), (c) and (d) of exercise period in the table shown on 2 (1).
2. The calculation was made based on the historical stock quotes by each classification below.
＜The 26th Series and the 27th Series stock option＞
The calculation was made based on the historical stock quotes during the period from May 3, 2010 to May 2, 2012.
Since the Company listed on the stock exchange on October 20, 2011, stock quotes were not available during the period
from May 3, 2010 to October 19, 2011. The Company selected several companies which were very close in resemblance
to the Company and used their historical quotes for the period.
＜The 28th stock option＞
The calculation was made based on the historical stock quotes during the period from September 29, 2010 to September
28, 2012.
Since the Company listed on the stock exchange on October 20, 2011, stock quotes were not available during the period
from September 29, 2010 to October 19, 2011. The Company selected several companies which were very close inresemblance to the Company and used their historical quotes for the period.
3. Since it is very difficult to make reliable estimates due to insufficient historical data, the remaining period was calculated
based on the assumption that the rights were exercised in the middle of each exercise period.
4. The Company estimates dividends to be zero since no dividends have been paid in the past.
5. It represents yields of Japanese government bonds corresponding to estimated remaining outstanding period.

4. Estimation of the number of stock options vested
The number of expired shares is estimated based on the historical turnover ratio.

- 46 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Deferred tax accounting)
1. Significant components of deferred tax assets and liabilities
FY 2011(As of December 31,
2011)
Deferred tax assets:
Excess depreciation for lump-sum depreciable
assetsExcess depreciation for depreciable assets
Excess amortization for deferred assets
Research and development expenses
Accounts payables-trade
Account payable-other
Provision for retirement benefits
Enterprise tax payable
Asset retirement obligation
Loss carried forward
Subtotal
Valuation allowance
Total deferred tax assets
Deferred tax liabilities
Total deferred tax liabilities
Net deferred tax assets(Unit: Thousand yen)
Y2012
(As of December 31,
2012)

1,702

1,094

763
265,563345,528
7,737
27,129
745
6,988
2,751
1,343,142
2,002,052(2,002,052)－

621
212,730
836,309
14,89919,905
601
5,203
3,143
1,454,943
2,549,452(2,549,452)
－

－
－

－
－

2. The reconciliation between the effective tax rates reflected in the financial statements and the statutory tax
rate is omitted since the Company reported loss before income taxes for the years ended December 31,
2011 and 2012.
(Equity in earnings)
None to be reported.
(Asset retirement obligations)
The Company has future restoration obligations related to leasehold contracts of office premises.
Carrying the balance of lease and guarantee deposits as an asset, the Company reasonably estimates nonrecoverable amounts of lease and guarantee deposits under lease contracts and records the amount attributable
to the respective fiscal year as expenses, instead of accounting for asset retirement obligations by recognizing aliability and an associated asset.
(Investment and rental property)
None to be reported.
(Segment information)【Segment information】
FY 2011 (From January 1, 2011 to December 31, 2011) and FY 2012 (From January 1, 2012 to December
31, 2012)
Segment information is omitted since the Company operates a single segment of pharmaceuticalbusinesses including research and development of pharmaceutical drugs as well as manufacturing andmarketing and other related activities.

- 47 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

【Related information】
FY 2011 (From January 1, 2011 to December 31, 2011)
1. Information by product and service
Information by product and service is omitted since external sales of a single service category account for morethan 90% of total net sales stated in the statement of income.
2. Information about geographical area
(1) Net sales
Net sales information about geographical area is omitted since external sales to Japanese customers account for
more than 90% of total net sales stated in the statement of income.
(2) Property, plant and equipment
All property, plant and equipment are located in Japan.
3. Information by major customer(Unit: Thousand yen)
Name of customer
Eizai Co., Ltd.

Net sales
1,872,471

Name of related segment
Pharmaceutical businesses including research anddevelopment of pharmaceutical drugs as well as
manufacturing marketing and other related activities.

FY 2012 (From January 1, 2012 to December 31, 2012)
1. Information by product and service
Information by product and service is omitted since external sales of a single service category account for morethan 90% of total net sales stated in the statement of income.
2. Information about geographical area
(1) Net sales
Net sales information about geographical area is omitted since external sales to Japanese customers account for
more than 90% of total net sales stated in the statement of income.
(2) Property, plant and equipment
All property, plant and equipment are located in Japan.
3. Information by major customer(Unit: Thousand yen)
Name of customer
Eizai Co., Ltd.

Net sales

Name of related segment
Pharmaceutical businesses including research anddevelopment of pharmaceutical drugs as well as
manufacturing marketing and other related activities.

1,928,233【Information about impairment loss on long-lived assets by reportable segment】
FY 2011 (From January 1, 2011 to December 31, 2011) and FY 2012 (From January 1, 2012 to December 31, 2012)
None to be reported.
【Information about the amortization and unamortized balance of goodwill by reportable segment】
FY 2011 (From January 1, 2011 to December 31, 2011) and FY 2012 (From January 1, 2012 to December 31, 2012)
None to be reported.
【Information about the gain recognized on negative goodwill by reportable segment】
FY 2011 (From January 1, 2011 to December 31, 2011) and FY 2012 (From January 1, 2012 to December 31, 2012)
None to be reported.

- 48 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Related parties information)
None to be reported.
(Per share information)
FY 2011(From January 1, 2011
to December 31, 2011)

FY 2012(From January 1, 2012
to December 31, 2012)

Net assets per share345.28 yen

Net assets per share

254.71 yen

Net loss per share(143.60) yen

Net loss per share(90.60) yen

While having potential dilutive stocks, diluted net income
per share is not provided since the Company reported net
loss per share.

While having potential dilutive stocks, diluted net income
per share is not provided since the Company reported net
loss per share.

On June 2, 2011, the Company conducted a 100-for-1
stock split. The following is the per share information if
the stock split would have been conducted at the
beginning of the fiscal year.
Net assets per share

365.42 yen

Net loss per share(59.33) yen

While having potential dilutive stocks, diluted net income
per share is not provided since the Company reported net
loss per share.

(Note1) The basis for calculating net loss per share is as follows:
FY 2011(From January 1, 2011
to December 31, 2011)
Net loss (thousand yen)
(2,104,513)
Amount not attributable to the shareholders of－common stock (thousand yen)
Net loss attributable to the shareholders of common(2,104,513)
stock (thousand yen)
Average number of shares outstanding during the
14,655,716
year (shares)
Description of potential dilutive stocks not included 24 types of Stock acquisitionin the earning-per-share calculation due to antirights (27,185 units) in
dilutive.
accordance with theCommercial Code of 1890
Article 280 (20) and (21), andCompanies Act Article 236,
238, and 239.

- 49 -FY 2012(From January 1, 2012
to December 31, 2012)(1,733,320)－(1,733,320)
19,130,825
23 types of Stock acquisitionrights (25,804 units) inaccordance with theCommercial Code of 1890
Article 280 (20) and (21), andCompanies Act Article 236,
238, and 239.

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012

(Note2) The basis for calculating net assets per share is as follows:
FY 2011(From January 1, 2011
to December 31, 2011)
Net assets (thousand yen)Amount to be deducted from net assets
Portion Stock acquisition right herein
Net assets attributable to the shareholders ofcommon stock (thousand yen)
Number of shares used in the calculation of net
assets per share (shares)

FY 2012(From January 1, 2012
to December 31, 2012)

6,605,564－－

4,899,957
27,167
27,167

6,605,564

4,872,790

19,130,825

19,130,825(Significant subsequent events)
FY 2012 (As of December 31, 2012)
Issuance of the 1st unsecured convertible bond with stock acquisition rights and the 29th Series stock option by
third party allotment
Based upon the resolution at the Company’s Board of Directors Meeting held on December 27, 2012, theCompany issued the 1st unsecured convertible bond with stock acquisition rights and the 29th Series stock
option on January 15, 2013 and has received the proceeds in the amount of 1,005,100 thousand yen on the samedate. The following summarizes the details.
(1) Purpose of the issuance
The issuance was made to procure funds for technology development of the existing pipeline andimplementation of new alternative technology, which help achieve steady growth in the value of theCompany’s business.
(2) Outline of the issuance(a) The 1st unsecured convertible bond with stock acquisition rights(1)The date of payment
January 15, 2013(2)Total number of stock acquition rights
40
Issue price per convertible bond:(3)The issue price of convertible bond and 25 million yen (100 yen per par value of 100 yen)stock acquisition rights
No cash payment required for stock acquisition rights associatedwith the convertible bond(4)Number of potential dilutive shares
3,311,258 shares(5)Amount of proceeds(6)Conversion price(7)Subscription or allotment(Allotted party)

1,000,000,000 yen
302 yenThe convertible bond with stock acquisition rights is allotted to thefollowing party by third-party allotment:
Wiz Healthcare PE Series 1 Investment Limited Liability Partnership
1,000,000,000 yen(8)Coupon(9)Other

The bond does not bear interest.
The preceding terms of subscription are conditional upon
notification of such terms coming into force in accordance with the
Financial Instruments and Exchange Act.

- 50 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2012(b) The 29th Series stock option(1)The date of allotment(2)Total number of stock acquisition rights(3)The issue price(4)Number of potential dilutive shares(5)Amount of proceeds(6)Exercise price(7)Subscription or allotment(Allotted party)(8)OtherJanuary 15, 201350
Total 5,100,000 yen (102,000 yen per each stock acquisition right)
1,326,250 shares
505,100,000 yen(detail)Issuance of stock acquisition rights
5,100,000 yen
Exercise of stock acquisition rights 500,000,000 yen
377 yenThe stock option is allotted to the following party by third-party
allotment:
Wiz Healthcare PE Series 1 Investment Limited Liability Partnership50
The preceding terms of subscription are conditional upon
notification of such terms coming into force in accordance with
the Financial Instruments and Exchange Act.

5. Other(1)Changes in Officers
None to be reported.
(2)Other
None to be reported.

- 51 -